INDEX

Volume Twenty-Four—January through December 1990

DICP, The Annals of Pharmacotherapy

JANUARY	Pages 1–118	JUNE	Pages 567–668	NOVEMBER Symposium	Pages S1–S56
FEBRUARY	Pages 119–224	JULY/AUGUST	Pages 669–802	DECEMBER	Pages 1153–1262
MARCH	Pages 225–346	SEPTEMBER	Pages 803–916		
APRIL	Pages 347–452	OCTOBER	Pages 917–1034		
MAY	Pages 453–566	NOVEMBER	Pages 1035–1152		

SUBJECT INDEX

A

Acebutolol, compared with nitrendipine (FF) 172; with hydrochlorothiazide, hypertension (DIAS) 157
Acetaminophen, duplicate labeling, aprolidine (L) 1232; interaction, zidovudine (FF) 758
Acetarsol, Stevens-Johnson syndrome (L) 99
Acyclovir, utilization (PEP) 624
Adult respiratory distress syndrome, stress ulcer prophylaxis, treatment (S) S8
Agranulocytosis, carbamazepine, monitoring (A) 1215; diclofenac (L) 1122
AIDS, clearinghouse, national (NC) 1152; drug approval process (NC) 668; incidence (NC) 1248; influenza vaccine (DIAS) 837; octreotide (DIAS) 951; pentamidine, aerosol, home care (SR) 592; phenytoin toxicity (CR) 698; thalidomide, aphthous stomatitis (SR) 1054
Albumin, concentration, cesarean, vaginal delivery (L) 328; phenytoin concentration, cancer (RPR) 923; utilization, cost (L) 101
Albuterol, compared with fenoterol, isoproterenol, epinephrine, metaproterenol, severe asthma (PA) 871; severe asthma (PA) 412
Alcohol, abuse, elderly (G) 971; intravenous, delirium tremens (L) 1120, (L) 545
Alpha-MD, compared with penbutolol (FF) 405
Alpha$_1$-acid glycoprotein, concentration, cesarean, vaginal delivery (L) 328
Aluminum hydroxide, gel, interaction, quinidine gluconate (SR) 252
Amenorrhea, antipsychotics (RPR) 176
American Association of Colleges of Pharmacy, see **Education and Research News (NC)**
American Board of Clinical Pharmacology, see **Association News (NC)**
American College of Clinical Pharmacy, see **Association News (NC)**
Amikacin, pharmacokinetics, volume of distribution, pediatrics (PED) 273
Aminocaproic acid, topical, hemophilia, dental extraction (DIAS) 160
Aminoglycosides, alteration, liver enzymes, bilirubin (RPR) 135; compared with ciprofloxacin, bone infections (RPR) 13; inhaled, cystic fibrosis (DIAS) 711; nephrotoxicity (DSP) 267; ototoxicity (DSP) 268; therapeutic monitoring (DSP) 270; volume of distribution, pediatrics (PED) 273, (L) 893
Aminophylline, compatibility, total parenteral nutrition (L) 324
Amiodarone, compared with theophylline (L) 1115; toxicity, audit (PEP) 1001
Amitriptyline, compared with clomipramine (FF) 741
Amoxapine, repetitive publication, case report (L) 646
Amoxicillin, colonization resistance (A) 64; compared with cefixime (FF) 492; diarrhea, Lactinex (SR) 382
Amphotericin B, compared with fluconazole (FF) 863; dilution (DIAS) 597; interaction, zidovudine (FF) 758; nephrotoxicity, sodium loading (CR) 940
Ampicillin, colonization resistance (A) 64; compared with sulbactam, drug utilization review (L) 782; costs (PEC) 203; prescribing patterns, pneumonia (PEP) 1220
Amrinone, pancytopenia (CR) 1172
Analgesia, postoperative, flumazenil (RPR) 1159
Anemia, aplastic, captopril (L) 543, carbamazepine, monitoring (A) 1215; **hemolytic,** human insulin (L) 887; **sickle cell,** nalbuphine compared with meperidine (L) 781
Anesthesia, local, buffered lidocaine (DIAS) 1180; cocaine, epinephrine, tetracaine (DIAS) 1181
Angina, unstable, heparin (DIAS) 385
Angiotensin-converting enzyme inhibitors, adverse reactions, review (DSP) 519; cough (DIAS) 1059; hemodynamics (DSP) 511; pharmacology (DSP) 496; review (DSP) 506; sublingual, test (L) 1116
Anion-exchange resins, with vancomycin, pseudomembranous colitis (DIAS) 70
Anistreplase, adverse reactions (FF) 612; clinical studies (FF) 609; compared with heparin (FF) 609; compared with streptokinase (FF) 609; pharmacokinetics (FF) 608; pharmacology (FF) 608; review (FF) 607
Analgesics, drug utilization (PEP) 878
An Opinion, see also, **Editorials; Dent, John, McCloy, Rory F., Garner, Andrew, Matthews, Jeffrey B., Rune, Simon, Blum, Andre L.,** Current and Future Drugs for Acid-Peptic Disease: A Plethora of Opinions on Possible Mechanisms of Action, 1226; **Maddox, Ray R.,** Specialization and Pharmacy's Future, 637; **Peloquin, Charles A.,** Fighting Tuberculosis with Old Weapons, 883; **Roach, Albert C., Kernodle, Douglas S., Kaiser, Allen B.,** Selecting Cost-Effective Antimicrobial Prophylaxis in Surgery: Are We Getting What We Pay For?, 183
Antacids, mechanism of action (O) 1226
Antibiotics, aspiration pneumonitis (S) 14; colonization resistance (A) 60; costs, team approach (PEC) 202; critical care, protocols (S) S17; order forms (L) 783; prophylaxis, cesarean section (TC) 841, computer monitoring (RPR) 351, dentistry, large-joint replacements (DIAS) 41; prescribing patterns, pneumonia (PEP) 1220; stress ulcer prophylaxis (S) S10
Anticholinergic agents, see **Parasympatholytic agents**
Anticoagulation, short-bowel syndrome (CR) 585
Antidepressants, drug utilization (PEP) 878; tricyclic, interaction, epinephrine, review (DIR) 190, immunodiagnostics, review (DIR) 188
H$_1$ Antihistamines, interaction, immunodiagnostics, review (DIR) 187
Antiinflammatory agents, ketorolac (FF) 1098; review, gastrointestinal bleeding (TC) 954
Antimetabolites, interaction, immunodiagnostics, review (DIR) 187
Antipsychotics, amenorrhea, galactorrhea (RPR) 176; seizures (A) 601
Antipyrine, pharmacokinetics, bioimpedence assessment (RPR) 575
Aprolidine, duplicate labeling, acetaminophen (L) 1232
Armstrong, Deborah K., Fellow, American College of Critical Care Medicine (NC) 802
Arthritis, osteo-, flurbiprofen compared with diclofenac (RPR) 920
Aspirin, compared with heparin, unstable angina (DIAS) 385; gastric bleeding, misoprostol (TC) 955, ranitidine (TC) 955, sucralfate (TC) 955
Association News (NC), ACCP Election Results, 346; BPS Announces Self-Study, 566; BPS Self-Study Process, 1033; 1991 Pharmacy World Congress, 1033; Nuclear Pharmacy Specialty Examination Scheduled, 914; Pharmacotherapy vis a vis Applied Pharmacology, 1152; Rho Chi Election Results, 452
Astemizole, no weight gain (RPR) 682
Asthma, anticholinergic agents (PA) 409; incidence (NC) 914; sympathomimetic agents (PA) 868
Atenolol, compared with heparin, unstable angina (DIAS) 385; compared with nitrendipine (FF) 172; compared with penbutolol (FF) 405; naproxen compared with sulindac, blood pressure response (RPR) 810
Atherosclerosis, coronary, edetic acid chelation (CR) 22
Atropine sulfate, mental status, elderly (DIR) 848; severe asthma (PA) 412
Azlocillin, with tobramycin, gentamicin, compared with ciprofloxacin, cystic fibrosis (RPR) 12
Aztreonam, compared with ciprofloxacin, bone infections (RPR) 13

B

Baldness, minoxidil with tretinoin (DIAS) 43
Baralgin, intravenous, compared with diclofenac sodium, renal colic (RPR) 361
BCG vaccine, interactions, review (DIR) 68, tuberculin skin tests, review (DIR) 186
Benet, Leslie Z., Distinguished Pharmaceutical Scientist Award, American Association of Pharmaceutical Scientists (NC) 118
Benztropine mesylate, abuse (DIAS) 40
Benzylpenicillin, colonization resistance (A) 64
Beta interferon, cancer, review (DSP) 765
Beta agonists, see **Sympathomimetic agents**
Bethanechol, cholinergic toxicity (L) 327
Beverages, carbonated, feeding tube irrigation (DIAS) 840
Bilirubin, alteration, aminoglycosides (RPR) 135
Binding, dexamethasone (RPR) 229, (L) 1010; phenytoin, AIDS (CR) 698
Bioavailability, see **Drugs, availability**
Bioimpedance, antipyrine pharmacokinetics, enzyme induction (RPR) 575
Biologic response modifiers, interferons, review (DSP) 761
Bipolar disorder, valproic acid (DIAS) 257
Bitolterol, compared with isoproterenol, asthma (PA) 871
Bleeding, postoperative, desmopressin acetate (DIAS) 475, 1235
Bleomycin, warts (DIAS) 952
Blood dyscrasias, carbamazepine, monitoring (RPR) 1166, (A) 1214
Blood levels, see **Therapeutic monitoring**
Board of Pharmaceutical Specialties, see also **Association News (NC)**; Nuclear Specialty Examination (NC) 914; pharmacotherapy petition (E) 73; pharmacy development (OP) 637; self-study (NC) 566, (NC) 1033
Book Reviews, About Your High Blood Pressure Medicines, 789; Antiepileptic Drugs, 3rd Edition (R.H. Levy, F.E. Dreifuss, R.H. Mattson, B.S. Meldrun, J.K. Penry), 209; Antimicrobial Chemotherapy, 2nd Edition (D. Greenwood), 1013; Antiviral Agents and Viral Diseases of Man, 3rd Edition (G.J. Galasso, R. J. Whitley, T.C. Merigan) 1237; Care of the Patient with HIV Infection, 648; Cerebrovascular Diseases (16th Research [Princeton] Conference on Cerebrovascular Drugs) (M.D. Ginsberg, W.D. Dietrich), 103; Chirality and Biological Activity (B. Holmstedt, H. Frank, B. Testa), 1013; Chronopharmacology in Therapy of the Epilepsies (F.E. Dreifuss, H. Meinardi, H. Stefan), 1125; Clinical Chemistry (H. Taylor), 442; Communication Skills in Pharmacy: A Practical Guide for Students and Practitioners (W.M. Tindall, R.S. Beardsley, C.L. Kimberlin), 647; Dissolution, Bioavailability & Bioequivalence (H.M. Abdou), 552; Drug Death: A Danger of Hospitalization (R.P. Hoffmann), 443; Drug Information: A Guide to Current Resources (B. Snow), 1125; Drug-Nutrient Interactions in AIDS Guidebook (C.F. Newman, B. Horn), 552; Drug-Test Interactions Handbook (J.G. Salway), 1012; Drugs and the Athlete (G.I. Wadler, B. Hainline), 330; Drugs, Vitamins and Minerals in Pregnancy (A.K. Henry, J. Feldhausen), 789; Effects of Disease on Clinical Laboratory Tests (R.B. Friedman, D.S. Young), 330; Fundamentals of Monitoring Psychoactive Drug Therapy (C.L. DeVane), 790; Hand-

book of Applied Therapeutics (L.Y. Young, M.A. Koda-Kimble, B.J. Guglielmo, W.A. Kradjan), 209; Handbook of Drug Therapy Monitoring (C.H. Brown), 894; Hypertension: Pathophysiology , Diagnosis, and Management (J.H. Laragh, B.M. Brenner), 442; Kinetics of Drug Decomposition: Basic Computer Solutions (W.J. Irwin), 1239; Medical Decision Making (H.C. Sox, Jr., M.A. Blatt, M.C. Higgins, K.I. Marton), 103; Merck Manual of Geriatrics, The (W.B. Abrams, R. Berkow), 1237; New Therapeutic Strategies in Hypertension (N.M. Kaplan, B.M. Brenner, J.H. Laragh), 329; 1989–1990 Pocketbook of Infectious Disease Therapy (J. Bartlett), 553; Nonsteroidal Anti-Inflammatory Drugs: Mechanisms and Clinical Use (A.J. Lewis, D.E. Furst), 895; Novel Drug Delivery and Its Therapeutic Application (L.F. Prescott, W.S. Nimmo), 1126; Nutritional Factors in Hypertension (H. Langford, B. Levine, L. Ellenbogen), 1126; Opioid Analgesia: Recent Advances in Systemic Administration. Advances in Pain Research and Therapy, Volume 14 (C. Benedetti, C.R. Chapman, G. Giron), 1014; Pharmaceutical Dosage Forms and Drug Delivery Systems, 5th Edition (H.C. Ansel, N.G. Popovich), 1238; Pharmaceuticals in Medical Imaging (D.P. Swanson, H.M. Chilton, J.H. Thrall), 895; Pocket Drug Guide (C.J. Gean, G.F.S. Hiatt, F.H. Meyers), 648; Prescription Drugs: An Indispensable Guide for People Over 50 (B.S. Katcher), 648; Presentation of Clinical Data (B. Spilker, J. Schoenfelder), 1012; Prevention of Sudden Cardiac Death, The (J.B. Kostis, M. Sanders), 1013; Principles of Clinical Toxicology, 2nd Edition (T.A. Gossel, J.D. Bricker), 894; Principles of Research Data Audit (A.E. Shamoo), 1237; Prostaglandins in Clinical Practice (W.D. Watkins, M.B. Peterson, J.R. Fletcher), 647; Psychopharmacology: An Introduction, 2nd Edition (R. Spiegel), 443; Quality of Life Assessments in Clinical Trials (B. Spilker), 1014; Regulating Change: The Regulation of Foods, Drugs, Medical Devices and Cosmetics in the 1990s (J.C. Peck, K.H. Rabin), 1015; Steroids in Diseases of the Central Nervous System (R. Capildeo), 1014
Books Received, 103, 210, 443, 649, 896, 1015, 1126, 1239
Bradycardia, cimetidine (L) 1124
Buprenorphine, heroin withdrawal (A) 728
Buspirone, abuse vs addiction (L) 785
Butoconazole, cream, thrombocytopenia (SR) 143

C

Calcification, soft tissue, renal failure (CR) 855
Campbell, R. Keith, Distinguished Service Award, American Association of Diabetes Educators (NC) 1248;1989 Outstanding Professor of Pharmacy Administration, NARD, Upjohn Company (NC) 346
Canada, prescribing, iron (IR) 874
Cancer, biologic response modifiers, clinical use, interferons (DSP) 761; phenytoin, albumin (RPR) 923; prostaglandin, flutamide, antiandrogen (FF) 616
Candidiasis, vulvovaginal (DSP) 1078
Captopril, aplastic anemia (L) 543; cough (DIAS) 1059; diabetic nephropathy (DIAS) 260; pharmacokinetics (DSP) 508; renal effects (DSP) 497
Carbamazepine, blood dyscrasias, monitoring 1166 (RPR), (A) 1214; toxicity, postoperative, myocardial infarction (CR) 822
Case Reports, see **Pharmacotherapy Case Reports**
Catheters, silicone central venous, theophylline absorption (L) 324
Cefaclor, colonization resistance (A) 64; compared with cefixime (FF) 492; compared with cephalexin, cephradine, cefadroxil, cefixime, cefuroxime axetil (DSP) 45; pharmacokinetics (DSP) 46
Cefadroxil, compared with cephalexin, cephradine, cefaclor, cefixime, cefuroxime axetil (DSP) 45; pharmacokinetics (DSP) 46
Cefamandole, compared with cefazolin, cost (L) 788, prophylaxis, cost (O) 183; compared with ciprofloxacin, cost (RPR) 15, pneumonia, bronchitis (RPR) 13; nephrotoxicity (TC) 263
Cefazolin, compared with cefamandole, cost (L) 7883, prophylaxis, cost (O) 183; compared with cefoxitin, cesarean section (TC) 841; compared with moxalactam, cesarean section (TC) 841; compared with ofloxacin, respiratory infection (RPR) 13; costs (PEC) 203; prescribing patterns, pneumonia (PEP) 1220
Cefixime, adverse reactions (FF) 492; compared with amoxicillin (FF) 492; compared with cefaclor (FF) 492; compared with cephalexin, cephradine, cefadroxil, cefaclor, cefuroxime axetil (DSP) 45; compared with trimethoprim/sulfamethoxazole (FF) 492; pharmacokinetics (DSP) 46, (FF) 490; review (FF) 489
Cefonicid, cost (PEC) 203
Cefoperazone, colonization resistance (A) 64
Cefotaxime, colonization resistance (A) 64; compared with ciprofloxacin, skin infections (RPR) 13; costs (PEC) 203
Cefotetan, compared with cefoxitin, DUE (L) 206
Cefoxitin, colonization resistance (A) 64; compared with cefazolin, cesarean section (TC) 841; compared with cefotetan, DUE (L) 206; compared with piperacillin, cesarean section (TC) 841; nonthrombocytopenic purpura (L) 206
Ceftazidime, colonization resistance (A) 64; nephrotoxicity (TC) 263
Ceftizoxime, drug utilization, empiric vs therapeutic regimens (L) 97
Ceftriaxone, colonization resistance (A) 64; compared with enoxacin, gonococcal urethritis (RPR) 13; prescribing patterns, pneumonia (PEP) 1220
Cefuroxime, axetil, compared with cephalexin, cephradine, cefadroxil, cefaclor, cefixime (DSP) 45; colonization resistance (A) 64; oral cephalosporins, bioavailability (L) 642; pharmacokinetics (DSP) 46; prescribing patterns, pneumonia (PEP) 1220
Cephalexin, compared with cephradine, cefadroxil, cefaclor, cefixime, cefuroxime axetil (DSP) 45; nephrotoxicity (TC) 263; pharmacokinetics (DSP) 46; stability, enteral nutrition (RPR) 130
Cephaloridine, nephrotoxicity (TC) 262
Cephalosporins, compared with ciprofloxacin, bone infections (RPR) 13; efficacy, comparison (DSP) 47; nephrotoxicity (TC) 262; oral, cefuroxime axetil, bioavailability (DSP) 642; pharmacokinetics (DSP) 46
Cephalothin, nephrotoxicity (TC) 262
Cephradine, colonization resistance (A) 64; compared with cephalexin, cefadroxil, cefaclor, cefixime, cefuroxime axetil (DSP) 45; pharmacokinetics (DSP) 46
Cerebellar syndrome, antibiotic prophylaxis (TC) 841; isoniazid (TC) 341
Certification, pharmacotherapy (E) 95, (E) 181, (L) 644
Cesarean section, antibiotic prophylaxis (TC) 841
Chelating agents, failure, coronary atherosclerosis (CR) 22
Chloramphenicol, compared with norfloxacin ophthalmic, conjunctivitis (L) 640; interaction, vaccines, review (DIR) 72
Chloroquine, interaction, vaccines, review (DIR) 73
Chlorotetracycline, colonization resistance (A) 64
Chlorpromazine, neuroendocrine effects (RPR) 178; seizures (A) 603
Chlorthalidone, compared with nitrendipine (FF) 172
Cholera vaccine, interactions, review (DIR) 68
Cholesterol, screening, community pharmacy (RPR) 817
Cholestyramine, pseudomembranous colitis (DIAS) 70; sensory/mixability preference (SR) 472
Chrischilles, Elizabeth A., awarded grants, Iowa Pharmacy Foundation (NC) 566
Cilastatin, compared with imipenem, coagulase-negative staphylococci (A) 717; with imipenem, compared with ciprofloxacin (RPR) 14
Cilazapril, cough (DIAS) 1059
Cimetidine, arrhythmia, hypotension (CR) 581; bradycardia (L) 1124; compared with omeprazole (FF) 397; dosing (S) S30; gastric bleeding, NSAIDs (TC) 955; immunoregulatory effects, review (A) 289; interaction, immunodiagnostics, review (DIR) 187, none, digoxin (DIR) 286; pediatrics (S) S42; stability, enteral nutrition (RPR) 130; thrombocytopenia (L) 1007
Ciprofloxacin, breast milk (SR) 703, (L) 1122; compared with aminoglycosides, aztreonam, cephalosporins, ureidopenicillins, imipenem, vancomycin, bone infection (RPR) 13; compared with azlocillin, tobramycin, gentamicin, cystic fibrosis (RPR) 12; compared with cefamandole, cost (RPR) 15, pneumonia, bronchitis (RPR) 13; compared with cefotaxime, skin infections (RPR) 13; compared with imipenem/cilastatin (RPR) 14; drug utilization review, DUE (PEC) 82; interaction, warfarin (SR) 27, theophylline (SR) 595; interstitial nephritis (SR) 379; neurotoxicity (CR) 138
Clindamycin, colonization resistance (A) 64; stability (L) 1008
Clinical studies, anistreplase (FF) 610; cefixime (FF) 492; chlorpromazine (A) 603; clomipramine (FF) 740; clozapine (A) 605; fluconazole (FF) 861; flumazenil (FF) 978; fluphenazine hydrochloride (A) 604; flurbiprofen (RPR) 920; flutamide (FF) 618; haloperidol (A) 605; hydroxyzine (TC) 484; ivermectin (IR) 429; moricizine (FF) 947; nafarelin acetate (FF) 1206; nitrendipine (FF) 170; omeprazole (FF) 396; ondansetron (S) S53; penbutolol (FF) 404; thioridazine (A) 604
Clomipramine, adverse effects (FF) 741; clinical studies (FF) 740; compared with amitriptyline (FF) 741; compared with clomipramine (FF) 741; compared with clorgiline (FF) 741; compared with desipramine (FF) 741; compared with imipramine (FF) 741; compared with nortriptyline (FF) 741; interactions (FF) 742; pharmacokinetics (FF) 739; pharmacology (FF) 739; review (FF) 739
Clonidine, heroin withdrawal (A) 726; toxicity, transdermal patch (PED) 1191
Clorgiline, compared with clomipramine (FF) 741
***Clostridium difficile*,** pseudomembranous colitis (DIAS) 70
Clozapine, dose error (L) 1012; seizures (A) 605
Coagulation factor VIII, interaction, immune globulin, cyclophosphamide, review (DIR) 189
Cocaine, with epinephrine, tetracaine, local anesthesia (DIAS) 1181
Colestipol, with vancomycin, pseudomembranous colitis (DIAS) 70
Colistin, colonization resistance (A) 64
Colitis, pseudomembranous, cholestyramine (DIAS) 70, vancomycin, with colestipol (DIAS) 70
Compatibility, aminophylline, total parenteral nutrition (L) 324
Compliance, cystic fibrosis (RPR) 689; hematologic monitoring, carbamazepine (RPR) 1166; lack, types (L) 641
Computers, critical care, review (CC) 1084; monitoring, antibiotics (RPR) 351; 13th Annual Symposium on Computer Applications in Medical Care (L) 888
Concentration, diazepam, infusion-site irritation (RPR) 678; ethanol, dipstick estimate (RPR) 358
Congenital malformations, perinatal mortality, diabetes (NC) 1034
Conjunctivitis, vancomycin (CR) 1050
Contrast media, see **Roentgenographic agents**
Cooper, Max, Sandoz Prize for Immunology, American Association of Immunologists (NC) 802
Corrections, see **Letters**
Corticosteroids, see **Steroids, cortico-**
Costs, see **Pharmacoeconomics**
Co-trimoxazole, see **Trimethoprim, with sulfamethoxazole; Sulfamethoxazole, with trimethoprim**
Coumermycin, coagulase-negative staphylococci (A) 717
Critical Care Therapeutics, Computers in Critical Care: Opportunities and Challenges, 1084; Mechanical Ventilation, 959; Norepinephrine in Septic Shock: Renewed Interest in an Old Drug, 153; Oxygen Homeostasis: Theory, Measurement, and Therapeutic Implications, 1195; Prophylaxis of Posttraumatic Seizures, 277
Cyclopentolate hydrochloride, mental status, elderly (DIR) 848
Cyclophosphamide, interaction, immune globulin, coagulation factor VIII (DIR) 189
Cyclosporine, hypertrichosis (CR) 365; thrombocytopenia (L) 1007
Cystic fibrosis, aminoglycosides, inhaled (DIAS) 711; compliance (RPR) 689

D–E

Danazol, compared with nafarelin acetate (FF) 1207; Evan's syndrome, systemic lupus erythematosus (L) 641
Daptomycin, coagulase-negative staphylococci (A) 717; pharmacokinetics (SR) 255
Dasta, Joseph F., Fellow, American College of Critical Care Medicine (NC) 452
Delirium tremens, intravenous alcohol (L) 545
Dentistry, antibiotic prophylaxis, large-joint replacements (DIAS) 41; topical aminocaproic acid, hemophilia (DIAS) 160
Dermatitis, exfoliative, trimethoprim/sulfamethoxazole (CR) 140, vancomycin (CR) 369
Desipramine, compared with clomipramine (FF) 741
Desmopressin acetate, enuresis (DIAS) 1179; postoperative bleeding (DIAS) 475, (L) 1235
Dexamethasone, aerosol, Parkinson's disease, dementia (SR) 707; binding (L) 1010, protein, serum (RPR) 229
Dextran, iron, parenteral, review (A) 162
Diabetes, insulin, oral sulfonylurea therapy (L) 1234; omega-3 fatty acid supplementation (DIAS) 258; pentoxifylline, proteinuria (RPR) 1043; perinatal mortality, congenital malformations (NC) 1034
Dialysis, hemo-, ganciclovir, pharmacokinetics (L) 544
Diarrhea, amoxicillin, Lactinex (SR) 382
DIAS Rounds, Accuracy of Home Pregnancy Tests, 712; ACE Inhibitor-Induced Cough, 1059; Amphotericin B Dilution, 597; Anabolic Steroid-Induced Psychiatric Reactions, 388; Antibiotic Prophylaxis in Dental Procedures, 41; Anticholinergic Drug Abuse, 40; Bleomycin Treatment of Warts, 952; Buffered Lidocaine in Local Anesthesia, 1180; Captopril in Diabetic Nephropathy, 260; Carbonated Beverages as Irrigants for Feeding Tubes, 840; Cardiac Dysfunction in Athletes Receiving Anabolic Steroids, 1060; dDAVP in Enuresis, 1179; Desmopressin Acetate in Postoperative Bleeding, 475; Doxepin in Smoking Cessation, 598; Guar Gum in Hyperlipidemia, 480; Heparin in Unstable Angina, 385; Hydrochlorothiazide Dosage in Hypertension, 157; Inhaled Aminoglycosides in Cystic Fibrosis, 711; Interferon in Multiple Sclerosis, 158; Methotrexate in Ectopic Pregnancy, 387; Minoxidil with Tretinoin in Baldness, 43; Nocturnal Leg Cramps, 599; Octreotide Use in AIDS, 951; Omega-3 Fatty Acid Supplementation in Noninsulin-Dependent Diabetes, 258; Potassium Supplements vs. Potassium-Sparing Diuretics, 710; Tetracaine/Adrenaline/Cocaine for Local Anesthesia, 1181; Thalidomide in Erythema Nodosum Leprosum, 482; Topical Aminocaproic Acid in Hemophiliac Patients Undergoing Dental Extraction, 160; Topical Minoxidil for Hair Loss in Women, 1062; Use of Influenza Vaccine in AIDS Patients, 837; Valproic Acid in Bipolar Disorder, 257; Verapamil in the Treatment of Schizophrenia, 838
Diazepam, concentration, infusion-site irritation (RPR) 678; stability, enteral nutrition (RPR) 130
Diclofenac, agranulocytosis (L) 786, (L) 1122; compared with flurbiprofen, osteoarthritis (RPR) 920; gastric bleeding, ranitidine (TC) 955; intramuscular, compared with intravenous Baralgin, renal colic (RPR) 361
***DICP, The Annals of Pharmacotherapy*,** research articles (E) 94
Diethylcarbamazine, compared with ivermectin, onchocerciasis (IR) 429
Diethylstilbestrol, compared with flutamide (FF) 618
Digitalis, intoxication, digoxin immune fab (A) 991
Digoxin, see also, **Lanoxin;** congestive heart failure (L) 1232; interaction, moricizine (FF) 749, nitrendipine (FF) 173, no interaction, cimetidine (DIR) 286
Digoxin immune fab, digitalis intoxication (A) 991
Diltiazem, erythematous macular skin eruptions (CR) 1046
Diphtheria-pertussis-tetanus vaccine, interactions, review (DIR) 68
Disodium etidronate, heterotopic ossification (DIAS) 71; Paget's disease (DIAS) 71
Disopyramide, compared with moricizine (FF) 748; interaction, rifampin (CR) 701

Dissolution rate, esophageal injury (RPR) 571
Doering, Paul L., Fellow, American Pharmaceutical Association Academy of Pharmacy Practice and Management (NC) 452
Dosage, estrogen, equipotent (L) 1009; lorazepam, neonates (L) 326; mefloquine, revised (NC) 1034
Dosage form, aerosol, aminoglycosides, cystic fibrosis (DIAS) 711, dexamethasone, Parkinson's disease, dementia (SR) 707, patient education (RPR) 927, pentamidine, AIDS, home care (SR) 592, ribavirin (TC) 735; **capsules,** Lanoxin, transition to tablets (SR) 381; **enema,** flecainide acetate (L) 1233; **intramuscular,** diclofenac, compared with intravenous Baralgin, renal colic (RPR) 361; **intramuscular,** midazolam, cardiorespiratory arrest and death (CR) 695; **intravenous,** alcohol, delirium tremens (L) 545, (L) 1120, immune globulin, quinidine-induced thrombocytopenia (CR) 693, ranitidine (L) 1123, ranitidine, time-motion study (SR) 590, streptomycin (CR) 826; **ophthalmic,** mental status changes, elderly (DIR) 847; **percutaneous,** transluminal coronary angioplasty, fluosol (FF) 1105; **powder,** cholestyramine, sensory/mixability preference (SR) 472; **sublingual,** ACEI test (L) 1116; **topical,** clonidine, toxicity (PED) 1191, minoxidil, hair loss in women (DIAS) 1062, vancomycin (CR) 1050
Doxepin, smoking cessation (DIAS) 598
Doxycycline, colonization resistance (A) 64
Drug abuse, benztropine mesylate, trihexyphenidyl hydrochloride (DIAS) 40; elderly (G) 971
Drug evaluations, see **Formulary Forum**
Drug information, bulletins, prescribing (IR) 87; continuing education, Kuwait (IR) 769; industry (L) 1117; nonprescription (L) 1118
Drug interactions, acetaminophen–zidovudine, review (FF) 758
  aluminum hydroxide–quinidine gluconate (SR) 252
  amiodarone–theophylline (L) 1115
  amphotericin–zidovudine, review (FF) 758
  anticoagulants–immunodiagnostics, review (DIR) 186
  H_1 antihistamines–immunodiagnostics, review (DIR) 187
  antimetabolites–immunodiagnostics, review (DIR) 187
  BCG–tuberculin skin tests, review (DIR) 186
  beta-adrenergic antagonists–epinephrine, review (DIR) 190
  cimetidine–digoxin, none (DIR) 286
  cimetidine–moricizine, review (FF) 749
  cimetidine, review (S) S38
  ciprofloxacin–theophylline (SR) 595
  ciprofloxacin–warfarin (SR) 27
  clomipramine, review (FF) 742
  corticosteroids–immunodiagnostics, review (DIR) 187
  detection, review (DIR) 982
  digoxin–cimetidine, none (DIR) 286
  digoxin–moricizine, review (FF) 749
  digoxin–nitrendipine, review (FF) 173
  disopyramide–rifampin (CR) 701
  epinephrine–beta-adrenergic antagonists, review (DIR) 190
  epinephrine–monoamine oxidase inhibitors, review (DIR) 190
  epinephrine–tricyclic antidepressants, review (DIR) 190
  fluconazole, review (FF) 864
  fluconazole–warfarin (SR) 1177
  fluoxetine–nortriptyline (L) 1008
  ganciclovir–zidovudine, review (FF) 758
  glipizide–trimethoprim/sulfamethoxazole (SR) 250
  hepatitis B vaccine–interleukin-2, review (DIR) 189
  histoplasmin–live-virus vaccines, review (DIR) 187
  immunodiagnostics–H_1 antihistamines, review (DIR) 187
  immunodiagnostics–anticoagulants, review (DIR) 186
  immunodiagnostics–antimetabolites, review (DIR) 187
  immunodiagnostics–corticosteroids, review (DIR) 187
  immunodiagnostics–interferon alfa, review (DIR) 189
  immunodiagnostics–tricyclic antidepressants, review (DIR) 188
  immunoglobulins–vaccines, review (DIR) 67
  interferon alfa–immunodiagnostics, review (DIR) 189
  interferon alfa–zidovudine, review (DIR) 189
  interleukin-2–hepatitis B vaccine, review (DIR) 189
  itraconazole, review (DSP) 150
  ketoconazole, review (DSP) 150
  lisinopril–lithium (SR) 946
  lithium–lisinopril (SR) 946
  live-virus vaccines–histoplasmin, review (DIR) 187
  live-virus vaccines–tuberculin skin tests, review (DIR) 187
  mexiletine–theophylline (SR) 471
  miconazole, review (DSP) 150
  monoamine oxidase inhibitors–epinephrine, review (DIR) 190
  moricizine–cimetidine, review (FF) 749
  moricizine–digoxin, review (FF) 749
  moricizine–propranolol, review (FF) 749
  moricizine–theophylline, review (FF) 749
  nitrendipine–digoxin, review (FF) 173
  nortriptyline–fluoxetine (L) 1008
  omeprazole, review (FF) 399
  penbutolol, review (FF) 404
  piroxicam–theophylline, none (RPR) 123
  propranolol–moricizine, review (FF) 749
  pyrimethamine–zidovudine, review (FF) 758
  quinidine gluconate–aluminum hydroxide (SR) 252
  quinidine polygalacturonate–sulfate tablets (RPR) 685
  H_2-receptor antagonists, review (S) S38
  rifampin–disopyramide (CR) 701
  sulfamethoxazole/trimethoprim–glipizide (SR) 250
  sulfamethoxazole/trimethoprim–zidovudine, review (FF) 758
  sulfdoxine–zidovudine, review (FF) 758
  theophylline–mexiletine (SR) 471
  theophylline–moricizine, review (FF) 749
  theophylline–amiodarone (L) 1115
  theophylline–ciprofloxacin (SR) 595
  theophylline–piroxicam, none (RPR) 123
  tricyclic antidepressants–epinephrine, review (DIR) 190
  tricyclic antidepressants–immunodiagnostics, review (DIR) 188
  trimethoprim/sulfamethoxazole–glipizide (SR) 250
  trimethoprim/sulfamethoxazole–zidovudine, review (FF) 758
  tuberculin skin tests–BCG vaccine, review (DIR) 186
  tuberculin skin tests–live-virus vaccines, review (DIR) 187
  vaccine–immunoglobulins (DIR) 67
  vaccine–vaccine (DIR) 67
  warfarin–ciprofloxacin (SR) 27
  warfarin–fluconazole (SR) 1177
  zidovudine–acetaminophen, review (FF) 758
  zidovudine–amphotericin B, review (FF) 758
  zidovudine–ganciclovir, review (FF) 758
  zidovudine–pyrimethamine, review (FF) 758
  zidovudine–sulfdoxine, review (FF) 758
  zidovudine–trimethoprim/sulfamethoxazole, review (FF) 758
  zidovudine–interferon alfa, review (DIR) 189
Drug Interactions and Reactions Update, Detecting Drug Interactions: A Review of the Literature, 982; Drug Interactions Involving Immunologic Agents: Part I. Vaccine–Vaccine, Vaccine–Immunoglobulin, and Vaccine–Drug Interactions, 67; Drug Interactions Involving Immunologic Agents: Part II. Immunodiagnostic and Other Immunologic Drug Interactions, 186; Effect of Cimetidine on Oral Digoxin Absorption, 286; Hemolytic Reactions to Nitrofurantoin in Patients With Glucose-6-Phosphate Dehydrogenase Deficiency: Theory and Practice, 1210; The Potential for Mental Status Changes Associated with Systemic Absorption of Anticholinergic Ophthalmic Medications: Concerns in the Elderly, 847
Drug preparations, amphotericin B, dilution (DIAS) 597; ranitidine, intravenous, time-motion study (SR) 590
Drug Selection Perspectives, Aminoglycosides: Another Perspective, 267; Angiotensin-Converting Enzyme Inhibitors: A Comparative Review, 506; Clinical Use of Biologic Response Modifiers in Cancer Treatment: An Overview. Part 1. The Interferons, 761; Drugs for Treatment of Vulvovaginal Candidiasis: Comparative Efficacy of Agents and Regimens, 1078; Imidazoles and Triazoles in Antifungal Therapy, 148; Oral Cephalosporins in Perspective, 45
Drug utilization, acyclovir (PEP) 624; albumin (L) 101; ampicillin/sulbactam (L) 782; ceftizoxime, empiric vs therapeutic regimens (L) 97; ciprofloxacin (PEC) 82; drug use process, review (A) 633; mood-modifying drugs (PEP) 878; neuroleptics, schizophrenia (RPR) 7; psychotropics (L) 784
Drug withdrawal, heroin, review (A) 721
Drugs, adverse reactions, acetarsol, Stevens-Johnson syndrome (L) 99; aminoglycosides, nephrotoxicity, review (DSP) 267, ototoxicity, review (DSP) 268; amphotericin B, nephrotoxicity, sodium loading treatment (CR) 940; amrinone, pancytopenia (CR) 1172; anabolic steroids, delusions, review (DIAS) 388; angiotensin-converting enzyme inhibitors, cough (DIAS) 1059; anistreplase, review (FF) 612; anticholinergic agents, mental status changes, elderly (DIR) 847; butoconazole cream, thrombocytopenia (SR) 143; carbamazepine, blood dyscrasias, monitoring, review (A) 1214; captopril, aplastic anemia (L) 543, cough (DIAS) 1059, review (DSP) 519; cefixime, review (FF) 492; cefoxitin, nonthrombocytopenic purpura (L) 206; cilazapril, cough (DIAS) 1059; cimetidine, arrhythmia, hypotension (CR) 581, bradycardia (L) 1124, thrombocytopenia (L) 1007; ciprofloxacin, interstitial nephritis (SR) 379, neurotoxicity (CR) 138; clomipramine, review (FF) 741; cycloplegic ophthalmic solution, psychosis (SR) 708; cyclosporine, hypertrichosis (CR) 365, thrombocytopenia (L) 1007; diclofenac, agranulocytosis (L) 1122; diltiazem, erythematous macular skin eruptions (CR) 1046; enalapril, cough (DIAS) 1059, review (DSP) 520; etretinate, ectropion, psoriasis (L) 1007; fluconazole, review (FF) 864; flumazenil, review (FF) 979; flutamide, review (FF) 620; gentamicin, nephrotoxicity (L) 1119; griseofulvin, review (A) 852; heparin, hyperkalemia (CR) 244; imipenem, seizure (CR) 467; insulin, human, hemolytic anemia (L) 887; iron dextran, review (A) 164; isoniazid, cerebellar syndrome (SR) 829; ivermectin, review (IR) 429; ketoconazole, hepatic enlargement (SR) 1175, review (DSP) 150; lisinopril, hyponatremia (CR) 1169, lithium toxicity (SR) 946, review (DSP) 520; metronidazole, peripheral neuropathy (CR) 19; miconazole, review (DSP) 150; midazolam, cardiac arrest (CR) 695; minoxidil, hypertrichosis (CR) 365; muromonab-CD3, aseptic meningitis (L) 1233; nafarelin acetate, review (FF) 1207; nitrendipine, review (FF) 173; nitrofurantoin, hemolysis, G-6-PD deficiency, review, 1210; norfloxacin, myasthenia gravis exacerbation (L) 207; omeprazole, review (FF) 398; oxybutynin, reflux esophagitis (CR) 583; penbutolol, review (FF) 404; pentamidine, hypomagnesemia (CR) 239; pergolide, hypotension (L) 543; perphenazine, priapism (CR) 246; phenothiazines, hirsutism (L) 1124; propylthiouracil, hepatic failure, encephalopathy (SR) 470; pyrazinamide, acute gout (L) 1115; quinidine, thrombocytopenia (CR) 693; rifampin, fixed eruption (SR) 947; spironolactone, review (A) 57; stanozolol, intracranial hypertension (L) 1234; steroids, anabolic, cardiac dysfunction, athletes (DIAS) 1060; streptokinase, anaphylaxis (CR) 546; sulfamethoxazole, with trimethoprim, exfoliative dermatitis (CR) 140; triazolam, review (TC) 389; trimethoprim, with sulfamethoxazole, exfoliative dermatitis (CR) 140; tryptophan, eosinophilia myalgia syndrome (L) 1009; vaccines, reporting (NC) 1248; valproic acid, excipients, diarrhea (SR) 832; vancomycin, exfoliative dermatitis (CR) 369; zidovudine, review (FF) 757
Drugs, availability, cefuroxime axetil (L) 642; quinidine polygalacturonate, sulfate (RPR) 685; related problems, structure, function (PEP) 1093; theophylline, psoriasis (CR) 464
Drugs, generic, approval process, irregularities (L) 98
Ectropion, etretinate, psoriasis (L) 1007
Edetic acid, chelation, coronary atherosclerosis (CR) 22
Editorials, see also, **An Opinion; Carter, Barry L.,** A Structure for Pharmacy Specialization, 1113; **Hutchinson, Richard A., Lewis, Richard K., Hatoum, Hind T.,** Inconsistencies in the Drug Use Process, 633; **McLeod, Donald C.,** Boards in Clinical Pharmacology: Portent for Pharmacy and Pharmacotherapy, 779, Pharmacotherapy: Part III. A Process of Certification, 95, Pharmacotherapy: Part IV. The Future of Specialization and Certification in Pharmacy, 181; **Stewart, Ronald B.,** Polypharmacy in the Elderly: A Fait Accompli?, 321; **Whitney, Harvey A. K., Jr.,** The Importance of Research Articles to *DICP, The Annals of Pharmacotherapy,* 94
Education, clinical, Rhode Island (L) 890, college of pharmacy (L) 642; college of pharmacy, hospital impact (ET) 422; continuing, drug information, Kuwait (IR) 769; patient, metered-dose inhaler (RPR) 927, preferences, elderly (RPR) 460
Education and Research News (NC), AACP Board of Directors Affirms Guidelines for Pharmacy's Certificate Programs, 117; Clinical Pharmacy Research Applications Invited, 117; Maryland School of Pharmacy Plans to Implement Entry-Level Pharm.D. Degree, 117; Number of Pharm.D. Degrees Awarded, 1033
Educational Events, 116, 223, 345, 451, 565, 665, 676, 913, 1034, 1150, 1242
Emergency department, ethanol concentrations, dipstick estimate (RPR) 358
Enalapril, cough (DIAS) 1059; pharmacokinetics (DSP) 509; renal effects (DSP) 498
Encainide, compared with moricizine (FF) 749
Endometriosis, review, nafarelin acetate (FF) 1204
Enema, flecainide acetate administration (L) 1233
Enoxacin, compared with ceftriaxone, gonococcal urethritis (RPR) 13
Enuresis, desmopressin acetate (DIAS) 1179
Enzyme induction, antipyrine pharmacokinetics, bioimpedence assessment (RPR) 575; pregnancy, 6-hydroxycortisol (RPR) 814; rifampin–disopyramide interaction (CR) 701
Enzymes, liver, alteration, aminoglycosides (RPR) 135
Eosinophilia myalgia syndrome, tryptophan (L) 1009
Epinephrine, compared with albuterol, isoproterenol, metaproterenol, asthma (PA) 871; interaction, beta adrenergic antagonists, review (DIR) 190, monoamine oxidase inhibitors, review (DIR) 190, tricyclic antidepressants, review (DIR) 190; with cocaine, tetracaine, local anesthesia (DIAS) 1181
Errors, medication, drug use process (A) 633
Erythema nodosum leprosum, thalidomide (DIAS) 482
Erythromycin, colonization resistance (A) 64
Esmolol, ventricular tachycardia (L) 99
Esophageal varices, sclerotherapy (S) S47
Esophagitis, reflux, oxybutynin (CR) 583
Esophagus, injury, dissolution rate (RPR) 571
Estramustine, compared with flutamide (FF) 618
Estrogen, compared with flutamide (FF) 618; dosing, equipotent (L) 1009
Ethanol, concentrations, saliva dipstick (RPR) 358
Etretinate, ectropion, psoriasis (PEP) 1007
Evan's syndrome, danazol, systemic lupus erythematosus (L) 641
Eyedrops, see **Solutions, ophthalmic**

F–G

Famotidine, dosing (S) S30; hemodynamics, intensive care (RPR) 1163; stability (L) 1010, total nutrient admixture (RPR) 232
FDA News (NC), AIDS Has Changed FDA, 668; Treatment IND for Fludarabine, 224; Zidovudine Approved for Asymptomatic HIV-Positive Patients, 452
Fellowships and Residencies, Arizona, University of Arizona, 1136, 1137; **California,** University of California, San Francisco, 1243, University of Southern California, 1132; **Connecticut,** Hartford Hospital, 1132, 1243; **Florida,** University of Florida Health Sciences Center, 109; **Georgia,** Emory University Hospital, 1132; **Idaho,** Idaho State University, 1132; **Illinois,** University of Illinois, 1136; **Michigan,** Detroit Receiving Hospital and University Health Center, 216, University of Michigan, 109; **Missouri,** University of Missouri–Kansas City, 1243, University of Missouri/Marion Merrell Dow, 336; **Nebraska,** Saint Joseph Hospital/Creighton University, 1136; **New York,** Memorial Sloan-Kettering Cancer Center, 661, State University of New York at Buffalo, 336; **North Carolina,** University of North Carolina/Glaxo, 1137; **North Dakota,** North Dakota State University, 216; **South Carolina,** University of South Carolina, 1137; **Texas,** University of Texas Health Science Center, 109, 216; **Wisconsin,** University of Wisconsin/Hazleton Laboratories, 336, 1243
Fenoterol, compared with albuterol, isoproterenol, asthma (PA) 871; severe asthma (PA) 412

Financial management, see **Pharmacoeconomics**

Flecainide, compared with moricizine (FF) 749; enema (L) 1233

Florida, self-care consultant law, assessment (RPR) 931

Fluconazole, adverse reactions (FF) 864; clinical studies (FF) 861; compared with amphotericin B (FF) 863; compared with itraconazole, ketoconazole, miconazole (DSP) 148; compared with ketoconazole (FF) 862; cryptococcal meningitis (L) 885; interaction, fluconazole (SR) 1177, review (FF) 864; pharmacokinetics (FF) 861; pharmacology (FF) 860; review (FF) 860

Fludarabine, treatment IND granted (NC) 224

Flumazenil, adverse reactions (FF) 979; clinical studies (FF) 978; pharmacokinetics (FF) 977; pharmacology (FF) 977; postoperative analgesia (RPR) 1159; review (FF) 976

Fluoroquinolones, see **Quinolones**

Fluosol, percutaneous, transluminal coronary angioplasty (FF) 1105

Fluoxetine, interaction, nortriptyline (L) 1008

Fluphenazine decanoate, expiration (L) 889; neuroendocrine effects (RPR) 178

Fluphenazine hydrochloride, neuroendocrine effects (RPR) 178; seizures (A) 604

Flurbiprofen, compared with diclofenac, osteoarthritis (RPR) 920

Flutamide, adverse reactions (FF) 620; clinical studies (FF) 618; compared with DES (FF) 618; compared with estramustine (FF) 618; compared with estrogen (FF) 618; compared with goserelin (FF) 619; compared with leuprolide (FF) 619; pharmacokinetics (FF) 617; pharmacology (FF) 616; review (FF) 616

Food and Drug Administration, drug reviews expedited, AIDS (NC) 668; generic drug approval process, irregularities (L) 98; *Haemophilus b influenza* vaccine approved (NC) 1152; zidovudine approved (NC) 452

Forms, antibiotic ordering (L) 783

Formulary Forum, Anistreplase: A Novel Thrombolytic Agent for Acute Myocardial Infarction, 607; Cefixime, 489; Clomipramine: A Tricyclic Antidepressant Effective in Obsessive-Compulsive Disorder, 739; Fluconazole: A New Triazole Antifungal Agent, 860; Flumazenil: A Benzodiazepine Antagonist, 976; Fluosol: An Oxygen-Delivery Fluid for Use in Percutaneous Transluminal Coronary Angioplasty, 1105; Flutamide: An Antiandrogen for Advanced Prostate Cancer, 616; Ketorolac: A Parenteral Nonsteroidal Antiinflammatory Drug, 1098; Moricizine: A Novel Antiarrhythmic Agent, 745; Nafarelin Acetate: A Gonadotropin-Releasing Hormone Agonist for the Treatment of Endometriosis, 1204; Nitrendipine: A New Dihydropyridine Calcium-Channel Antagonist for the Treatment of Hypertension, 167; Omeprazole: A Novel Antisecretory Agent for the Treatment of Acid-Peptic Disorders, 393; Penbutolol: A New Beta-Adrenergic Blocking Agent, 403; Zidovudine Update: 1990, 754

Gal, Peter, Clinical Practice Award, American College of Clinical Pharmacy (NC) 916

Galactorrhea, antipsychotics (RPR) 176

Gamma interferon, cancer, review (DSP) 765

Ganciclovir, interaction, zidovudine (FF) 758; pharmacokinetics, hemodialysis (L) 544

Gastroesophageal reflux, respiratory symptoms, review (TC) 1064

Gastrointestinal bleeding, nonsteroidal antiinflammatory drugs (TC) 954

General News (NC), Controversial Resolutions Adopted at the 1990 USPC Quinquennial Meeting, 566; Journals' Clinical Research Reports Evaluated, 914; Mickey Leland Honored with a Memorial Lecture, 1033; Reimbursement to and Prescribing by Nurses, 346; Small-Town Hospital Attracts International Scientists, 1033

Gentamicin, dose determination, pharmacokinetics, geriatrics (TM) 29; nephrotoxicity (L) 1119; pharmacokinetics, volume of distribution, pediatrics (PED) 273; with azlocillin, compared with ciprofloxacin, cystic fibrosis (RPR) 12

Gerbino, Philip P., Vice President for Professional Programs, Philadelphia College of Pharmacy and Science (NC) 346

Geriatrics, alcohol, drug abuse (G) 971; anticholinergic agents, ophthalmic, mental status (DIR) 847; dosage form, transition from Lanoxin capsules to tablets (SR) 381; education, patient preferences (RPR) 460; gentamicin, dose determination (TM) 29; polypharmacy (ED) 321; prescribing, United Kingdom (G) 533

Geriatrics and Gerontology, A Profile of Alcohol and Prescription Drug Abuse in a High-Risk Community-Based Elderly Population, 971; Drug Prescribing in Residential Homes for Elderly People in the United Kingdom, 533

Glipizide, interaction, trimethoprim/sulfamethoxazole (SR) 250

Glucose-6-phosphate dehydrogenase, deficiency, nitrofurantoin hemolysis (DIR) 1210

Goserelin, compared with flutamide (FF) 619

Gout, pyrazinamide, 1115

Griseofulvin, adverse reactions (A) 852; pharmacokinetics (A) 851; review (A) 851

Guar gum, hyperlipidemia (DIAS) 480

H–K

***Haemophilus b* conjugate vaccine,** approved (NC) 1152

Hair, loss, women, minoxidil (DIAS) 1062

Haloperidol, neuroendocrine effects (RPR) 178

Health care, home, pentamidine, aerosol, AIDS (SR) 592

Heart failure, congestive, digoxin (L) 1232; spironolactone (A) 54

Hemodynamics, angiotensin-converting enzyme inhibitors (DSP) 511; famotidine, intensive care (RPR) 1163; norepinephrine, septic shock (CC) 154; phenylephrine, septic shock (CR) 936; H_2-receptor antagonists (S) S35

Hemolysis, nitrofurantoin, G-6-PD deficiency, (DIR) 1210

Hemophilia, aminocaproic acid, topical, dental extraction (DIAS) 160

Heparin, angina, unstable (DIAS) 385; compared with anistreplase (FF) 609; compared with aspirin, atenolol, unstable angina (DIAS) 385; hyperkalemia (CR) 244; short-bowel syndrome (CR) 585

Hepatitis B vaccine, interaction, interleukin-2, review (DIR) 189; interactions, review (DIR) 68

Heroin, dependence, withdrawal (A) 722

HHS News (NC), Orphan Products Grants Awarded, 224

Hirsutism, cyclosporine, minoxidil (CR) 365; phenothiazines (L) 1124

Histamine H_2-antagonists, aspiration pneumonitis (S) S14; continuous infusion (S) S28; hemodynamic effects (S) S35; mechanism of action (O) 1226; pediatrics (S) S42; stress ulcer prophylaxis (S) S10

Histoplasmin, interaction, live virus vaccines (DIR) 187

History, therapeutic monitoring, Japan (IR) 629

Homatropine, mental status, elderly (DIR) 848

Homeopathy, thyroid drugs, therapeutic potential (SR) 26

Hydralazine, compared with nitrendipine (FF) 172

Hydrochlorothiazide, compared with nitrendipine (FF) 170; with acebutolol, hypertension (DIAS) 157

6-Hydrocortisol, elimination, pregnancy (RPR) 814

Hydrogen ion concentrations, esophageal injury (RPR) 571

Hydroxyzine, pain relief (L) 1123; with meperidine, morphine, review (TC) 485

Hyperaldosteronism, spironolactone (A) 54

Hyperkalemia, heparin (CR) 244

Hyperlipidemia, guar gum (DIAS) 480

Hypertension, hydrochlorothiazide, with acebutolol (DIAS) 157; intracranial, stanozolol (L) 1234; naproxen compared with sulindac, atenolol response (RPR) 810; spironolactone (A) 53; trauma, labetalol (CR) 235; treatment program, cost (PEC) 304

Hyperventilation, positron emission tomography, review (RPR) 456

Hypoglycemia, glipizide-trimethoprim/sulfamethoxazole interaction (SR) 250

Hypokalemia, potassium supplements compared with potassium-sparing diuretics (DIAS) 710

Hypomagnesemia, pentamidine (CR) 239

Hyponatremia, lisinopril (CR) 1169

Hypotension, cimetidine (CR) 581; pergolide (L) 543

Ibrahim, Michel A., editor, *American Journal of Public Health* (NC) 802

Ibuprofen, gastric bleeding, misoprostol (TC) 955, ranitidine (TC) 955

Imipenem, compared with ciprofloxacin, bone infections (RPR) 13; dosing (L) 236; seizure (CR) 467; with cilastatin, coagulase-negative staphylococci (A) 717, compared with ciprofloxacin (RPR) 14

Imipramine, compared with clomipramine (FF) 741; compared with moricizine (FF) 749

Immune globulin, interaction, cyclophosphamide, coagulation Factor VIII, review (DIR) 189, vaccines, review (DIR) 67; quinidine-induced thrombocytopenia (CR) 693

Immunization, adverse reaction reporting (NC) 1248; adult, standards (NC) 1248

Immunodiagnostic agents, interaction, antimetabolites, review (DIR) 187, cimetidine, review (DIR) 187, corticosteroids (DIR) 187, tricyclic antidepressants, review (DIR) 188; interactions, H_1 antihistamines, review (DIR) 187, review (DIR) 186

Immunomodulation, cimetidine, review (A) 289

Indomethacin, gastric bleeding, ranitidine (TC) 955; interaction, vaccines, review (DIR) 76

Industry, validity of information (L) 1117

Influenza vaccine, AIDS (DIAS) 837; interactions, review (DIR) 68

Insulin, human, hemolytic anemia (L) 887; with oral sulfonylureas, diabetes (L) 1234

Interferon, cancer, review (DSP) 761; multiple sclerosis (DIAS) 158

Interferon, alfa, cancer, review (DSP) 761; interaction, theophylline, review (DIR) 189, zidovudine, review (DIR) 189

Interleukin-2, interaction, hepatitis B vaccine, review (DIR) 189

International Pharmaceutical Federation, see **Association News (NC)**

International Reports, Drug Information Centers as Bases for Continuing Education Programs in Kuwait, 769; Impact of a Drug Bulletin on the Knowledge, Perception of Drug Utility, and Prescribing Behavior of Physicians, 87; Ivermectin: A Long-Acting Microfilaricidal Agent, 426; Prescribing and Dispensing Practices for Oral Iron Tablets: A Canadian Experience, 874; Therapeutic Drug Monitoring Services at Kyushu University Hospital in Japan, 629

Ipratropium bromide, severe asthma (PA) 412

Iron, dextran, adverse reactions (A) 164, parenteral, review (A) 162; prescribing, Canada (IR) 874

Irritant, diazepam, concentration (RPR) 678

Isoetharine, severe asthma (PA) 412

Isoniazid, cerebellar syndrome (SR) 829

Isoproterenol, compared with albuterol, epinephrine, fenoterol, metaproterenol, bitolterol, asthma (PA) 871

Isradipine, compared with nitrendipine (FF) 170

Itraconazole, compared with fluconazole, ketoconazole, miconazole (DSP) 148

Ivermectin, adverse reactions (IR) 429; chemistry (IR) 426; pharmacokinetics (IR) 428; review (IR) 426

Japan, therapeutic monitoring, history (IR) 629

Jones, Mark E., awarded grants, Iowa Pharmacy Foundation (NC) 566

Ketoconazole, compared with fluconazole (FF) 862; compared with fluconazole, itraconazole, miconazole (DSP) 148; hepatic enlargement (SR) 1175

Ketorolac, parenteral NSAID (FF) 1098

Kuwait, continuing education, drug information centers (IR) 769

L–N

Labeling, acetaminophen, aprolidine (L) 1232

Labetalol, hypertension, tachycardia, trauma (CR) 235

Lactinex, amoxicillin-induced diarrhea (SR) 382

Lanoxin, see also, **Digoxin;** transition from capsules to tablets (SR) 381

Legislative News (NC), Pharmacy Freedom of Choice Bill Passed, 566

Leland, Mickey, memorial lecture (NC) 1033

Letters, Abnormal Metabolism of Phenylbutazone After Overdosage, 783; Acetarsol-Induced Stevens-Johnson Syndrome, 99; Administration of ACEI Test Sublingually, 1116; Aminophylline via TPN, 324; An Aminoglycoside Dosing Regimen in a Morbidly Obese Patient, 100; Antibiotic Order Forms in the Nursing Home, 783; Aseptic Meningitis Associated with Muromonab-CD3, 1233; Assessment of Pediatric Theophylline Measurements, 887; Aztreonam Adverse Reactions, 438; Bethanechol-Induced Cholinergic Toxicity in Diabetic Neuropathy, 327; Blind Versus Nonblind Review: A Reevaluation of Selected Medical Journals, 1117; Captopril Versus Enalapril: Cough Versus Pancreatitis, 438; Captopril-Associated Aplastic Anemia, 543; Ceftizoxime Drug Utilization Evaluation: Empiric Versus Therapeutic Regimens, 97; Cimetidine-Associated Thrombocytopenia, 1007; Ciprofloxacin *Staphylococcus aureus* Resistance, 439; Clindamycin Stability, 1008; Clinical Pharmacy as Perceived by a Foreign Physician, 208; Combined Insulin and Oral Sulfonylureas—How Sweet it *Isn't!*, 1234; Considerations in Establishing Expiration Dates for Fluphenazine Decanoate Multiple-Dose Vials, 889; Danazol for Evan's Syndrome Due to SLE, 641; Development of Acute Gout Secondary to Pyrazinamide in a Patient Without a Prior History of Gout, 1115; Drop Size and Systemic Adverse Effects in Timolol Ophthalmic Solution, 439; Drug Fever with a Shift to the Left, 782; Drug Utilization Evaluation of Cefotetan Versus Cefoxitin in a Large Teaching Hospital, 206; Drug Utilization Review of Ampicillin/Sulbactam, 782; Ectropion: An Adverse Effect of Etretinate Therapy for Psoriasis, 1007; Effect of Continuous Arteriovenous Hemodialysis on Ganciclovir Pharmacokinetics, 544; Intracranial Hypertension Associated with Stanozolol, 1234; Endpoints for Usage of Cardiac Drugs, 886; Equipotent Dosing of Estrogens, 1009; Esmolol for the Treatment of Ventricular Tachycardia, 99; Estimating Pharmacokinetic Values, 208; Exacerbation of Myasthenia Gravis by Norfloxacin, 207; Flecainide Acetate Administration by Enema, 1233; Fluconazole Success After Amphotericin B and Flucytosine Failure in Cryptococcal Meningitis, 885; IV Alcohol in Prevention of Delirium Tremens, 545; Initial Drug Noncompliance, 641; Lorazepam Dosing in Neonates: Application of Objective Sedation Scores, 326; Lorazepam and Sleep Quality, 325; Medication(?)—Not Drug, 890; Nalbuphine vs. Meperidine in Sickle Cell Anemia, 781; Netilmicin Sulfate Stability in Combination with Metronidazole or Ranitidine Hydrochloride in NaCl 0.9% Infusion, 440; Nonthrombocytopenic Purpura Induced by Cefoxitin, 206; Norfloxacin Ophthalmic Versus Chloramphenicol in Bacterial Conjunctivitis and Blepharoconjunctivitis, 640; Pergolide-Induced Hypotension, 543; Plicamycin: Bolus or Infusion?, 885; Possible Cyclosporine-Associated Thrombocytopenia, 1007; Possible Hemolytic Anemia Associated with Human Insulin Therapy, 887; Possible Theophylline-Amiodarone Interaction, 1115; Precaution with Titrating Nortriptyline After the Use of Fluoxetine, 1008; Psychotropic Drug Data Request, 784; SCAMC: A Meeting of the "Computer" Minds, 888; Serum Concentration of Alpha$_1$-Acid Glycoprotein and Albumin Following Cesarean Section and Vaginal Delivery, 328; Simple Ways to Promote Cost Containment, 546; Spanish-Language Pharmacists, 101; Teaching and Education of Future Clinicians, 642; The "Abuse" of Oxygen, 1118; The Generic Drug Scandal and Its Implications for Pharmacy Professionals, 98; Theophylline Plasma Concentrations and Silicone Central Venous Catheter: A Potential Source of Error, 324; Tryptophan and Eosinophilia Myalgia Syndrome, 1009; Use of Digoxin in Patients with Sinus Rhythm and Heart Failure, 1232; Validity of Information Received from Pharmaceutical Companies, 1117; Warning: Acetaminophen and Aprolidine Both Labeled Apronal, 1232; What Nonprescription Medication Are You Taking, Mrs. Jones?, 1118

Comments/Authors' Replies, Agranulocytosis Caused by Diclofenac?, 786, Agranulocytosis from Diclofenac Illustrates Problem in Reporting ADRs, 1122, Albumin Use in Hospitals, 101, Aminoglycoside Volume of Distribution in Children, 893, Ciprofloxacin Excretion into Breast Milk, 1122, Clinical Education in Rhode Island, 890, Cost Effectiveness of Cefazolin Compared with Cefamandole, 788, Desmopressin in Postoperative Bleeding, 1235, Dexamethasone Binding, 1010, Duteplase not Alteplase, 1236, Famotidine Stability, 1010, Hydroxizine for the Potentiation of Pain Relief, 1123, IV Alcohol in Prevention of Delirium Tremens, 1120, Imipenem Dosing, 1236, Incidence of Adverse Reactions Caused by Contrast Media, 547, Intravenous Ranitidine Admixtures, 1123, Lack of Abuse Potential with Buspirone, 785, Liver Function Tests, 787, Nephrotoxicity from Once-Daily Dosing of Gentamicin, 1119, Neurologic Toxicity Related to Ciprofloxacin, 891, Oral Cephalosporins, 642, Pharmacotherapy and Certification, 644, Pharmacy Specialization, 1011, Phenothiazines and Hirsutism, 1124, Repetitive Publication of Amoxapine and NMS Case Report, 646, Streptokinase-Induced Reactions, 546
Corrections, BPS Appointments, 329, Book Price, 1124, Cimetidine-Induced Bradycardia, 1124, Propofol Dosage, 102, Seizure Activity Associated with Antipsychotic Therapy, 1012; Transposed Figures, 1236
Leukopenia, carbamazepine, monitoring (A) 1215
Leuprolide, compared with flutamide (FF) 619
Lidocaine, buffered, local anesthesia (DIAS) 1180
Lipids, total nutrient admixtures, review (A) 298
Lisinopril, hyponatremia (CR) 1169; interaction, lithium (SR) 946; pharmacokinetics (DSP) 509; renal effects (DSP) 498
Lithium, interaction, lisinopril (SR) 946
Lorazepam, dosing, neonates (L) 326; sleep quality (L) 325
Maddox, Ronald W., Don Blanton Award, North Carolina Pharmaceutical Association (NC) 916
Measles, revised vaccination policy (NC) 224
Measles-mumps-rubella vaccine, interactions, review (DIR) 68
Mechanism of action, antacids, histamine H_2-antagonists (O) 1226
Meetings, see **Educational Events**
Mefloquine, revised dosing regimen (NC) 1034
Meningitis, aseptic, muromonab-CD3 (L) 1233; cryptococcal, fluconazole (L) 885
Meningococcal vaccine, single-dose vials (NC) 1248
Meperidine, combined with hydroxyzine (TC) 485; compared with hydroxyzine and morphine (TC) 487; compared with nalbuphine, sickle cell anemia (L) 781; neurologic toxicity (L) 891
Metabolism, theophylline, psoriasis (CR) 464
Metaproterenol, compared with albuterol, epinephrine, isoproterenol, asthma (PA) 871; severe asthma (PA) 412
Methadone, heroin withdrawal (A) 722
Methotrexate, ectopic pregnancy (DIAS) 387
Metoclopramide, compared with ondansetron (S) S53
Metoprolol, compared with penbutolol (FF) 405
Metronidazole, peripheral neuropathy (CR) 19
Mexiletine, interaction, theophylline (SR) 471
Miconazole, compared with fluconazole, itraconazole, ketoconazole (DSP) 148
Midazolam, cardiorespiratory arrest (CR) 695
Milk, breast, ciprofloxacin (SR) 703, (L) 1122
Miller, Jacques, Sandoz Prize for Immunology, American Association of Immunologists (NC) 802
Minoxidil, hypertrichosis (CR) 365; topical, hair loss in women (DIAS) 1062; with tretinoin, baldness (DIAS) 43
Misoprostol, critical care (S) S32; gastric bleeding, NSAIDs (TC) 955
Molindone, seizures (A) 605
Monoamine oxidase inhibitors, interaction, epinephrine, review (DIR) 190
Moricizine, adverse reactions (FF) 750; clinical studies (FF) 747; compared with disopyramide (FF) 748; compared with encainide, flecainide, imipramine (FF) 749; compared with propranolol (FF) 748; compared with quinidine (FF) 749; interactions (FF) 749; pharmacokinetics (FF) 746; pharmacology (FF) 745; review (FF) 745
Morphine, compared with hydroxyzine (TC) 485; compared with hydroxyzine and meperidine (TC) 487
Moxalactam, compared with cefazolin, cesarean section (TC) 841
Multiple sclerosis, interferon (DIAS) 158
Muromonab-CD3, aseptic meningitis (L) 1233
Myasthenia gravis, exacerbation, norfloxacin (L) 207
Myocardial infarction, anistreplase, review (FF) 607
Myotonic dystrophy, tocainide (DIAS) 69
Nafarelin acetate, adverse reactions (FF) 1207; compared with danazol (FF) 1207; pharmacokinetics (FF) 1206; pharmacology (FF) 1206; review (FF) 1204
Nafcillin, costs (PEC) 203
Nahata, Milap C., Chairman, *DICP* Editorial Council (NC) 118; Education Award, American College of Clinical Pharmacy (NC) 916; President-Elect, American College of Clinical Pharmacy (NC) 118
Nalbuphine, compared with meperidine, sickle cell anemia (L) 781
Naltrexone, heroin withdrawal (A) 730
Naproxen, compared with sulindac, atenolol response (RPR) 810; gastric bleeding, misoprostol (TC) 955, ranitidine (TC) 955
Neisseria gonorrhoeae, resistance (NC) 668
Nephritis, interstitial, ciprofloxacin (SR) 379
Nephrotoxicity, aminoglycosides (DSP) 267; amphotericin B, sodium loading (CR) 940; cephalosporins (TC) 263; diabetic, captopril (DIAS) 260; gentamicin (L) 1119
Neuroleptics, see **Psychotherapeutics**
Neuropathy, peripheral, metronidazole (CR) 19
Neurotoxicity, ciprofloxacin (CR) 138
New Publications, see **Book Reviews, Books Received**
News and Comments, 117, 224, 346, 452, 566, 668, 801, 914, 1033, 1152, 1248; see also, **Association News, Education and Research News, FDA News, General News, HHS News, USPHS–CDC News, VIP News**
Nifedipine, compared with nitrendipine (FF) 170
Nitrendipine, adverse reactions (FF) 173; compared with acebutolol (FF) 172; compared with atenolol (FF) 172; compared with chlorthalidone (FF) 172; compared with hydralazine (FF) 172; compared with hydrochlorothiazide (FF) 170; compared with isradipine (FF) 170; compared with nifedipine (FF) 170; compared with propranolol (FF) 172; compared with verapamil (FF) 170; interaction, digoxin (FF) 173; pharmacokinetics (FF) 169; pharmacology (FF) 167; review (FF) 167
Nitrofurantoin, hemolysis, G-6-PD deficiency (DIR) 1210
Nomenclature, abuse versus addiction (L) 785; medication versus drug (L) 890
Nonthrombocytopenic purpura, cefoxitin (L) 206
Norepinephrine, septic shock, review (CC) 153
Norfloxacin, compared with spectinomycin, gonococcal urethritis (RPR) 13; myasthenia gravis exacerbation (L) 207; ophthalmic, compared with chloramphenicol, conjunctivitis (L) 640
Nortriptyline, compared with clomipramine (FF) 741; interaction, fluoxetine (L) 1008
Nutrition, enteral, stability, cephalexin, cimetidine, diazepam, propranolol (RPR) 130; **parenteral,** compatibility, aminophylline (L) 324, critical care (S) S31; famotidine stability (RPR) 232, review (A) 296

O–P

Obesity, ranitidine, pharmacokinetics (RPR) 1040; tobramycin dosing (L) 100
Obstetrics, cesarean, vaginal delivery, alpha$_1$-acid glycoprotein, albumin concentration (L) 328
Octreotide, AIDS (DIAS) 951
Oddis, Joseph A., Remington Honor Medal Award, American Pharmaceutical Association, 346
Ofloxacin, compared with cefazolin, respiratory infection (RPR) 13
Omega-3 fatty acid, supplementation, noninsulin-dependent diabetes (DIAS) 258
Omeprazole, adverse reactions (FF) 399; compared with cimetidine, ranitidine (FF) 397; critical care (S) S33; interactions (FF) 399; pharmacokinetics (FF) 395; pharmacology (FF) 393; review (FF) 389; toxicology (FF) 395
Onchocerciasis, ivermectin (IR) 429
Ondansetron, compared with metoclopramide (S) S53
Opinions, see **An Opinion; Editorials**
Opioids, dependence, withdrawal (A) 721
Orphenadrine citrate, nocturnal leg cramps (DIAS) 600
Ossification, heterotopic, disodium etidronate (DIAS) 71
Ototoxicity, aminoglycosides (DSP) 268
Overdose, verapamil, sustained release (SR) 705
Oxacillin, colonization resistance (A) 64
Oxybutynin, reflux esophagitis (CR) 583
Oxygen, abuse (L) 1118; homeostasis, critical care, review (CC) 1195
Paget's disease, disodium etidronate (DIAS) 71
Pain, hydroxyzine (TC) 484, potentiation (L) 1123
Pancytopenia, amrinone (CR) 1172
Parasympatholytic agents, abuse (DIAS) 40; compared with beta$_2$-agonists, severe asthma (PA) 412; ophthalmic, mental status, elderly (DIR) 847; with beta$_2$-agonists, severe asthma (PA) 413
Pediatrics, aminoglycosides, volume of distribution (PED) 273, (L) 893; neonates, lorazepam dosing (L) 326; propylthiouracil, hepatic failure, encephalopathy (SR) 470; H_2-receptor antagonists (S) S42; theophylline, monitoring (L) 887
Pediatrics (PED), Aminoglycoside Volume of Distribution in Pediatric Patients, 273; Clonidine Patch Toxicity, 1191
Peer review, blind versus nonblind (L) 1117
Penbutolol, adverse reactions (FF) 404; compared with alpha-MD (FF) 405; compared with atenolol (FF) 405; compared with metoprolol (FF) 405; compared with pindolol (FF) 405; compared with propranolol (FF) 405; interactions (FF) 404; pharmacokinetics (FF) 403; pharmacology (FF) 403; review (FF) 403
Penicillin G potassium, costs (PEC) 203
Pentamidine, aerosol, AIDS, home care (SR) 592; hypomagnesemia (CR) 239
Pentostatin, treatment IND (NC) 104
Pentoxifylline, proteinuria, diabetes (RPR) 1043
Pergolide, hypotension (L) 543
Perphenazire, clinical studies (A) 605; priapism (CR) 246
Personnel Placement, see separate section: **ADVERTISERS**
pH, see **Hydrogen ion concentrations**
Pharmacoeconomics, ciprofloxacin, drug utilization review, drug use evaluation (PEC) 82; college of pharmacy based, hospital services (ET) 422; cost containment, promotion (L) 546; costs, antibiotics (PEC) 202, cefazolin compared with cefamandole, prophylaxis (O) 183, hypertension treatment program (PEC) 304; critical care (S) S24; drug utilization evaluation, cefotetan compared with cefoxitin (L) 206
Pharmacoeconomics (PEC), A Team Approach to Reduce Antibiotic Costs, 202; Ciprofloxacin Drug Utilization Review and Prospective Drug Use Evaluation, 82; Effect of a Clinical Pharmacist Program on the Cost of Hypertension Treatment in an HMO Family Practice Clinic, 304; Impact of College of Pharmacy-Based Educational Services Within the Hospital, 422
Pharmacoepidemiology, survey design, cluster sampling (PEP) 310
Pharmacoepidemiology (PEP), A Nationwide Survey of Antibiotic Prescribing Patterns and Clinical Outcomes in Patients with Bacterial Pneumonia, 1220; Acyclovir Use and Its Surveillance in a General Population, 624; Adjusting for Clustering in Survey Research, 310; Amiodarone: A Postmarketing Evaluation of Monitoring for Drug-Induced Toxicity, 1001; Drug-Related Problems: Their Structure and Function, 1093; Self-Reported Neuroendocrine Effects of Antipsychotics in Women: A Pilot Study, 176; The Saskatchewan Program for Rational Drug Therapy: Effects on Utilization of Mood-Modifying Drugs, 878
Pharmacokinetics, amikacin, volume of distribution, pediatrics (PED) 273; aminoglycosides, volume of distribution, pediatrics (PED) 273, (L) 893; anistreplase, 608; antipyrine, bioimpedance assessment, enzyme induction (RPR) 575; captopril (DSP) 508; cefixime (FF) 490; cephalosporins (DSP) 46; clomipramine (FF) 739; daptomycin (SR) 255; dexamethasone binding (RPR) 229; enalapril (DSP) 509; estimation (L) 208; fluconazole (DSP) 148, (FF) 861; flumazenil (FF) 977; flutamide (FF) 617; ganciclovir, hemodialysis (L) 544; gentamicin, geriatrics (TM) 29, volume of distribution, pediatrics (PED) 273; griseofulvin (A) 851; itraconazole (DSP) 148; ivermectin (IR) 428; ketoconazole (DSP) 148; lisinopril (DSP) 509; miconazole (DSP) 148; moricizine (FF) 746; nafarelin acetate (FF) 1206; nitrendipine (FF) 169; omeprazole (FF) 395; ranitidine, obese women (RPR) 1040; spironolactone (A) 52; theophylline, psoriasis (CR) 464; tobramycin, volume of distribution, pediatrics (PED) 273; zidovudine (FF) 754
Pharmacology, angiotensin-converting enzyme inhibitors (DSP) 496; anistreplase (FF) 608; applied, pharmacotherapy (NC) 1152; clinical, governing board (E) 779; clomipramine (FF) 739; fluconazole (FF) 860; flumazenil (FF) 977; flutamide (FF) 616; moricizine (FF) 745; nafarelin acetate (FF) 1206; nitrendipine (FF) 167; omeprazole (FF) 393
Pharmacotherapy, applied pharmacology (NC) 1152; certification (E) 95, (E) 181, (L) 644; hypertension treatment program, cost (PEC) 304; impact, clinical pharmacology board (E) 779; perception of foreign physician (L) 208; specialization (E) 181, (L) 1011
Pharmacotherapy Case Reports, A Suspected Case of Trimethoprim/Sulfonamide-Induced Localized Exfoliation, 140; Altered Theophylline Metabolism in Patients with Psoriasis, 464; Apparent Failure of Edetic Acid Chelation Therapy for the Treatment of Coronary Atherosclerosis, 22; Cimetidine-Associated Adverse Reaction, 581; Drug-Induced Hypertrichosis: Case Report and Review of the Literature, 365; Enzyme Induction: Rifampin–Disopyramide Interaction, 701; Heparin-Induced Hyperkalemia, 244; High-Dose Phenylephrine Infusion in the Hemodynamic Support of Septic Shock, 936; Intravenous Immune Globulin for the Treatment of Presumed Quinidine-Induced Thrombocytopenia, 693; Intravenous Streptomycin, 826; Oral Anticoagulation in Patients with Short-Bowel Syndrome, 585; Oxybutynin-Induced Reflux Esophagitis, 583; Pancytopenia Secondary to Short-Term High Dose Intravenous Infusion of Amrinone, 1172; Perphenazine-Induced Priapism, 246; Persistent Metronidazole-Induced Peripheral Neuropathy, 19; Possible Intramuscular Midazolam-Associated Cardiorespiratory Arrest and Death, 695; Potential Neurologic Toxicity Related to Ciprofloxacin, 138; Prolonged Labetalol Infusion for Management of Severe Hypertension and Tachycardia in a Critically Ill Trauma Patient, 235; Reports of Erythematous Macular Skin Eruptions Associated with Diltiazem Therapy, 1046; Seizure Activity with Imipenem Therapy: Incidence and Risk Factors, 467; Severe Hypomagnesemia Induced by Pentamidine, 239; Severe Hyponatremia: An Association With Lisinopril?, 1169; Severe Phenytoin Intoxication as a Result of Altered Protein Binding in AIDS, 698; Sodium Loading Treatment for Amphotericin B-Induced Nephrotoxicity, 940; Topical Vancomycin for the Treatment of *Staphylococcus epidermidis* and Methicillin-Resistant *Staphylococcus aureus* Conjunctivitis, 1050; Toxic Carbamazepine Concentrations Following Cardiothoracic Surgery and Myocardial Infarction, 822; Vancomycin-Associated Exfoliative Dermatitis, 369
Pharmacy, see also **Pharmacotherapy; clinical,** education (L) 642, nonprescription drug information (L) 1118; **community,** cholesterol screening (RPR) 817; **consultant,** evaluation (SR) 833; **development,** Board of Pharmaceutical Specialties (OP) 637; **international,** Spanish-speaking (L) 101; pharmacology, pharmacotherapy (E) 779; specialization (E) 1113
Phenethicillin, colonization resistance (A) 64
Phenobarbital, prophylaxis, posttraumatic seizures (CC) 281
Phenothiazines, hirsutism (L) 1124
Phenylbutazone, abnormal metabolism (L) 783

Phenylephrine, septic shock (CR) 936
Phenytoin, albumin, cancer (RPR) 923; interaction, vaccines, review (DIR) 77; prophylaxis, posttraumatic seizures (CC) 281; toxicity (CR) 698
Physicians, prescribing, drug bulletin impact (IR) 87
Pimozide, seizures (A) 605
Pindolol, compared with penbutolol (FF) 405
Piperacillin, colonization resistance (A) 64; compared with cefoxitin, cesarean section (TC) 841
Pirenzepine, critical care (S) S31
Piroxicam, gastric bleeding, misoprostol (TC) 955, ranitidine (TC) 955; no interaction, theophylline (RPR) 123
Plicamycin, bolus versus infusion (L) 885
Pneumococcal vaccine, interactions, review (DIR) 68
Pneumonia, prescribing patterns (PEP) 1220
Pneumonitis, aspiration, treatment (S) S12
Poliovirus vaccine, interactions, review (DIR) 68
Positron emission tomography, cerebral blood flow, review (RPR) 456
Postmarketing surveillance, amiodarone, toxicity (PEP) 1001
Potassium, supplements, compared with potassium-sparing diuretics (DIAS) 710
Pregnancy, 6-hydroxycortisol, elimination (RPR) 814; ectopic, methotrexate (DIAS) 387; home test, accuracy (DIAS) 712
Prescribing, bulletins, impact (IR) 87; elderly, United Kingdom (G) 533; Florida, self-care consultant law (RPR) 931; iron, Canada (IR) 874; methods of influence, review (A) 417, (A) 537; patterns, pneumonia (PEP) 1220
Priapism, perphenazine (CR) 246
Primaquine phosphate, availability (NC) 914
Professional organizations, specialty development (E) 181
Proglumide, critical care (S) S31
Promazine, seizures (A) 604
Prophylaxis, antibiotic, cesarean section (TC) 841, computer monitoring (RPR) 351, dentistry, large-joint replacements (DIAS) 41; cefazolin compared with cefamandole, cost (O) 183; Lactinex, amoxicillin-induced diarrhea (SR) 382; seizures, posttraumatic (CC) 277; zidovudine (FF) 757
Propofol, dosage, correction (L) 102
Propoxyphene, heroin withdrawal (A) 726
Propranolol, compared with moricizine (FF) 748; compared with nitrendipine (FF) 172; compared with penbutolol (FF) 405; stability, enteral nutrition (RPR) 130
Propylthiouracil, hepatic failure, encephalopathy (SR) 470
Proteinuria, pentoxifylline, diabetes (RPR) 1043
Psoriasis, theophylline, pharmacokinetics (CR) 464
Psychosis, cycloplegic eyedrops (SR) 708
Psychotherapeutic agents, drug utilization (L) 784; neuroleptics, drug utilization, schizophrenia (RPR) 7
Publishing, research articles, *DICP, The Annals of Pharmacotherapy* (E) 94
Pulmonary and Allergy, Should Anticholinergics Be Used in Acute Severe Asthma?, 409; Sympathomimetics for Acute Severe Asthma: Should Only Beta$_2$-Selective Agonists be Used?, 868
Pyrazinamide, acute gout, 1115
Pyrimethamine, drug interactions, zidovudine (FF) 758

Q–R

Quinidine, compared with moricizine (FF) 749; gluconate, interaction, aluminum hydroxide gel (SR) 252; left shift, differential (L) 782; polygalacturonate compared with sulfate bioavailability (RPR) 685; thrombocytopenia, immune globulin (CR) 693
Quinine sulfate, nocturnal leg cramps (DIAS) 599
Quinolones, colonization resistance (A) 64; compared with parenteral therapy (RPR) 11
Rabies vaccine, interactions, review (DIR) 71
Ranitidine, compared with omeprazole (FF) 397; dosing (S) S30; gastric bleeding, NSAIDs (TC) 955; intravenous (L) 1123; intravenous admixtures, time-motion study (SR) 590; pediatrics (S) S42; pharmacokinetics, obese women (RPR) 1040
Renal colic, diclofenac sodium im, compared with Baralgin iv (RPR) 361
Renal failure, soft tissue calcification (CR) 855
Renal function, angiotensin-converting enzyme inhibitors (DSP) 496
Research, methodology, cluster sampling (PEP) 310
Research/Practice Reports, A Retrospective Study of Compliance with Recommended Hematologic Monitoring of Carbamazepine, 1166; An Assessment of the Drug Therapy Education Preferences of an Interdisciplinary Group Interested in the Elderly, 460; Assessment of the Florida Pharmacist Self-Care Consultant Law Using Patient Profile and Prescription Audit Methods, 931; Bioimpedance Assessment of Antipyrine Pharmacokinetics Before and After Enzyme Induction, 575; Characterization of Dexamethasone Binding in Normal and Uremic Human Serum, 229; Clinical Utility of a Saliva Alcohol Dipstick Estimate of Serum Ethanol Concentrations in the Emergency Department, 358; Comparative Bioavailability Characteristics of Commercial Quinidine Polygalacturonate and Sulfate Tablets, 685; Compliance Among Adults with Cystic Fibrosis, 689; Correlation of Delayed Peak Concentration with Infusion-Site Irritation Following Diazepam Administration, 678; Correlation of Free Phenytoin to Serum Albumin in Cancer Patients, 923; Effect of Naproxen and Sulindac on Blood Pressure Response to Atenolol, 810; Effects of Pentoxifylline on Proteinuria in Normotensive Patients with Diabetes Mellitus, 1043; Evaluation of Pharmacists' Practice in Patient Education when Dispensing a Metered-Dose Inhaler, 927; Flurbiprofen Versus Diclofenac for the Treatment of Osteoarthritis of the Knee, 920; Hemodynamic Status During Famotidine Infusion, 1163; Hyperventilation-Induced Reduction in Cerebral Blood Flow: Assessment by Positron Emission Tomography, 456; Increased 6-Hydroxycortisol Excretion in Pregnant Women: Implication of Drug-Metabolizing Enzyme Induction, 814; Influence of Dissolution Rate and pH of Oral Medications on Drug-Induced Esophageal Injury, 571; Intramuscular Diclofenac Sodium Versus Intravenous Baralgin in the Treatment of Renal Colic, 361; Lack of Effect of Piroxicam on Theophylline Clearance in Healthy Volunteers, 123; Lack of Weight Gain Associated with Short-Term Astemizole Treatment, 682; Oral Fluoroquinolone Versus Mono- or Combination Parenteral Therapy in the Management of Bacterial Infections: A Critical Appraisal, 11; Outcome of Cholesterol Screening in a Community Pharmacy, 817; Patterns of Neuroleptic Usage in Continuously Hospitalized Chronic Schizophrenic Patients: Evidence for Development of Drug Tolerance, 7; Pharmacokinetics of Ranitidine in Morbidly Obese Women, 1040; Postoperative Analgesic Requirements Following Flumazenil Administration, 1159; Prospective Evaluation of Liver Function Tests in Patients Treated with Aminoglycosides, 135; Reducing the Duration of Prophylactic Antibiotic Use Through Computer Monitoring of Surgical Patients, 351; Stability of Drugs with Enteral Nutrient Formulas, 130; Stability of Famotidine in a 3-in-1 Total Nutrient Admixture, 232
Resistance, coagulase-negative staphylococci (A) 714; colonization, antibiotic selection (A) 60; *Neisseria gonorrhoeae* (NC) 668
Review Articles, A Model of Methods for Influencing Prescribing: Part I. A Review of Prescribing Models, Persuasion Theories, and Administrative and Educational Methods, 417; A Model of Methods for Influencing Prescribing: Part II. A Review of Educational Methods, Theories of Human Inference, and Delineation of the Model, 537; A Review of Carbamazepine's Hematologic Reactions and Monitoring Recommendations, 1214; Cimetidine: An Immunomodulator, 289; Clinical Issues Regarding the Use of Total Nutrient Admixtures, 296; Coagulase-Negative Staphylococci: Incidence, Pathogenicity, and Treatment in the 1990s, 714; Effect on Colonization Resistance: An Important Criterion in Selecting Antibiotics, 60; Griseofulvin: A New Look at an Old Drug, 851; Parenteral Iron Dextran Therapy, 162; Pharmacologic Interventions for the Treatment of Opioid Dependence and Withdrawal, 721; Seizure Activity Associated with Antipsychotic Therapy, 601; Soft Tissue Calcification in Renal Failure, 855; Spironolactone: A Re-Examination, 52; Treatment of Digitalis Intoxication with Emphasis on the Clinical Use of Digoxin Immune Fab, 991
Rno Chi, see **Association News (NC)**
Rhode Island, clinical education (L) 890
Ribavirin, aerosol, respiratory syncytial virus (TC) 735
Rifampin, coagulase-negative staphylococci (A) 717; fixed drug eruption (SR) 947; interaction, disopyramide (CR) 701
Robinson, J. Daniel, *DICP* Editorial Council (NC) 118
Roentgenographic agents, adverse reactions, incidence (L) 547
Rubella vaccine, interactions, review (DIR) 71
Rybak, Michael J., Merck Foundation Fellowship Award in Infectious Disease (NC) 566

S–T

Saskatchewan, national drug therapy program (PEP) 878
Schentag, Jerome J., Achievement for Sustained Contributions to the Literature of Hospital Pharmacy, ASHP (NC) 346; Distinguished Young Alumnus Award, Philadelphia College of Pharmacy and Science (NC) 346
Schizophrenia, drug utilization, neuroleptics (RPR) 7; verapamil (DIAS) 838
Scopolamine, mental status, elderly (DIR) 849
Sedative/hypnotics, drug utilization (PEP) 878
Seizures, antipsychotics (A) 601; ciprofloxacin–theophylline interaction (SR) 595; imipenem (CR) 467; posttraumatic, prophylaxis, review (CC) 277
Shock, septic, norepinephrine, review (CC) 153, phenylephrine (CR) 936
Short Reports, A Case of Lisinopril-Induced Lithium Toxicity, 946; A Double-Blind, Placebo-Controlled Study of the Efficacy of Lactinex in the Prophylaxis of Amoxicillin-Induced Diarrhea, 382; Cerebellar Syndrome Caused by Isoniazid, 829; Chemical Stability of Suramin in Commonly Used Infusion Fluids, 1056; Ciprofloxacin Penetration into Human Breast Milk: A Case Report, 703; Clinical Pharmacokinetics of Daptomycin, 255; Dexamethasone Aerosol Use in an Asthmatic Nursing-Home Patient with Parkinson's Disease and Dementia, 707; Effect of Aluminum Hydroxide Gel on Quinidine Gluconate Absorption, 252; Excipients in Valproic Acid Syrup May Cause Diarrhea: A Case Report, 832; Experience with Home Aerosolized Pentamidine Treatment in Patients with AIDS, 592; Fixed Drug Eruption Following Rifampin Treatment, 947; Interaction Between Theophylline and Mexiletine, 471; Massive Hepatic Enlargement With Fatty Change Associated With Ketoconazole, 1175; Possible Potentiation of Warfarin by Fluconazole, 1177; Propylthiouracil-Induced Hepatic Failure and Encephalopathy in a Child, 470; Seizure with Ciprofloxacin and Theophylline Combined Therapy, 595; Sensory/Mixability Preference Evaluation of Cholestyramine Powder Formulations, 472; Severe Reversible Thrombocytopenia Resulting from Butoconazole Cream, 143; Severe Verapamil (Sustained-Release) Overdose, 705; Suspected Ciprofloxacin-Induced Interstitial Nephritis, 379; Symptomatic Hypoglycemia Secondary to a Glipizide–Trimethoprim/Sulfamethoxazole Drug Interaction, 250; Thalidomide: Treatment of Severe Recurrent Aphthous Stomatitis in Patients with AIDS, 1054; The Pharmacist as a Health Consultant—Ten Years Later, 833; Therapeutic Potential of Two Over-the-Counter Thyroid Hormone Preparations, 26; Time-Motion Study of Intravenous Ranitidine Admixtures, 590; Toxic Psychosis Following Cycloplegic Eyedrops, 708; Transition from Lanoxin Capsules to Lanoxin Tablets in the Debilitated Elderly, 381
Short-bowel syndrome, oral anticoagulation (CR) 585
Sleep, quality, lorazepam (L) 325
Smallpox vaccine, interactions, review (DIR) 71
Smoking, cessation, doxepin (DIAS) 598
Sodium, loading, amphotericin B, nephrotoxicity (CR) 940
Software Reviews, CYBERLOG. Perspectives in Rational Management: Hypertension, 896; Human Drug Kinetics: A Course of Simulated Experiments (L. Saunders, D. Ingram, S.H.D. Jackson), 790; OncoDisc, 791; SIcalc: Software Program for Interconversions of S.I. Units and Traditional Units, 1015
Solutions, irrigating, carbonated beverages (DIAS) 840; ophthalmic, cycloplegic, psychosis (SR) 708
Somatostatin, critical care (S) S33
Specialties, pharmacotherapy (E) 181; pharmacy, development, Board of Pharmaceutical Specialties (O) 637; structure (E) 1113
Spectinomycin, compared with norfloxacin, gonococcal urethritis (RPR) 13
Spironolactone, adverse reactions (A) 57; congestive heart failure, hyperaldosteronism (A) 54; hypertension (A) 53; pharmacokinetics (A) 52; review (A) 52
Stability, cephalexin, enteral nutrition (RPR) 130; cimetidine, enteral nutrition (RPR) 130; clindamycin (L) 1008; diazepam, enteral nutrition (RPR) 130; famotidine (L) 1010, total nutrient admixture (RPR) 232; propranolol, enteral nutrition (RPR) 130; suramin (SR) 1056
Stanozolol, intracranial hypertension (L) 1234
Staphylococcus, aureus, epidermidis, vancomycin (CR) 1050; coagulase-negative, review (A) 716
Steroids, anabolic, cardiac dysfunction, athletes (DIAS) 1060, psychiatric reactions (DIAS) 388; **cortico-,** interaction, immunodiagnostics (DIR) 187
Stevens-Johnson syndrome, acetarsol (L) 99
Stewart, Ronald B., Russell R. Miller Award, American College of Clinical Pharmacy (NC) 916
Stimulants, drug utilization (PEP) 878
Stomatitis, aphthous, thalidomide, AIDS (SR) 1054
Streptokinase, anaphylaxis (L) 546; compared with anistreplase (FF) 609
Streptomycin, intravenous (CR) 826
Stringer, Kathleen A., grant awarded, New Investigators Program, American Association of Colleges of Pharmacy (NC) 118
Sucralfate, gastric bleeding, NSAIDs (TC) 955
Sulbactam, with ampicillin, drug utilization review (L) 782
Sulfadoxine, interaction, zidovudine (FF) 758
Sulfamethoxazole, with trimethoprim, colonization resistance (A) 64, compared with cefixime (FF) 492, exfoliative dermatitis (CR) 140; interaction, glipizide (SR) 250, zidovudine (FF) 758, left shift, differential (L) 782
Sulfonylureas, oral, with insulin, diabetes (L) 1234
Sulindac, compared with naproxen, atenolol response (RPR) 810; gastric bleeding, ranitidine (TC) 955
Suramin, stability (SR) 1056
Surgery, postoperative analgesia, flumazenil (RPR) 1159; postoperative bleeding, desmopressin acetate (DIAS) 475, (L) 1235
Sympatholytic agents, interaction, epinephrine, review (DIR) 190
Sympathomimetic agents, asthma, review (PA) 868
Symposium, Achieving pH Control in the Critically Ill Patient: the Role of Continuous Infusion of H$_2$-Receptor Antagonists, S28; Aspiration Pneumonitis: Risk Factors and Management of the Critically Ill Patient, S12; Assessing the Nutritional Needs of the Critically Ill Patient, S20; Controlling Gastric pH: the Impact of Newer Agents on the Critically Ill Patient, S31; Hemodynamic Effects of H$_2$-Receptor Antagonists, S35; Ondansetron: a New Entity in Emesis Control, S51; Overview of the Safety Profile of the H$_2$-Receptor Antagonists, S38; Pathophysiologic Changes in the Critically Ill Patient: Risk Factors for Ulceration and Altered Drug Metabolism, S5; Pathophysiology, Monitoring, and Management of the Ventilator-Dependent Patient: Considerations for Drug Therapy, Emphasis on Stress Ulcer Prophylaxis, S8; Pharmacoeconomics: Therapeutic and Economic Considerations in Treating the Critically Ill Patient, S24; Rational Use of Antibiotics in the Critically Ill Patient, S17; Sclerotherapy for Esophageal Varices, S47; Use of H$_2$-Receptor Antagonists in Children, S42
Systemic lupus erythematosus, Evan's syndrome, danazol (L) 641

Tachycardia, trauma, labetalol (CR) 235; ventricular, esmolol (L) 99

Teicoplanin, coagulase-negative staphylococci (A) 717

Tests, ACEI, sublingual (L) 1116; home pregnancy, accuracy (DIAS) 712; liver function, aminoglycosides (RPR) 135, (L) 787; positron emission tomography, review (RPR) 456; therapeutic drug monitoring, review (TM) 1070

Tetanus, incidence (NC) 452

Tetanus toxoid, interactions, review (DIR) 71

Tetracaine, with cocaine, epinephrine, local anesthesia (DIAS) 1181

Tetracycline, colonization resistance (A) 64

Thalidomide, aphthous stomatitis, AIDS (SR) 1054; erythema nodosum leprosum (DIAS) 482

Theophylline, absorption, silicone central venous catheter (L) 324; compared with amiodarone (L) 1115; interaction, ciprofloxacin (SR) 595, interferon alfa, review (DIR) 189, mexiletine (SR) 471; monitoring, children (L) 887; no interaction, piroxicam (RPR) 123; pharmacokinetics, psoriasis (CR) 464

Therapeutic Controversies, Antibiotic Prophylaxis in Cesarean Section, 841; Cephalosproin-Induced Nephrotoxicity: Does It Exist?, 262; Gastroesophageal Reflux and Respiratory Symptoms: Is There an Association? Proposed Mechanisms and Treatment, 1064; Potentiation of Pain Relief with Hydroxyzine: A Therapeutic Myth?, 484; Preventing Upper Gastrointestinal Bleeding in Patients Receiving Nonsteroidal Antiinflammatory Drugs, 954; Triazolam—An "Abused" Drug by the Lay Press?, 389; Using Estimated Creatinine Clearance for Individualizing Drug Therapy: A Reassessment, 1185; What is the Clinical Role of Aerosolized Ribavirin?, 735

Therapeutic Monitoring, Accuracy of Pharmacokinetic Dose Determination of Gentamicin in Geriatric Patients, 29; Therapeutic Drug Monitoring Analysis Systems for the Physician Office Laboratory: A Review of the Literature, 1070

Therapeutic monitoring, Japan (IR) 629; aminoglycosides (DSP) 270; antibiotics, computers (RPR) 351; anticoagulants, short-bowel syndrome (CR) 585; laboratory analysis systems, review (TM) 1070; theophylline, children (L) 887

Thioridazine, neuroendocrine effects (RPR) 178; seizures (A) 604

Thiothixene, neuroendocrine effects (RPR) 178; no seizures (A) 605

Thrombocytopenia, butoconazole cream (SR) 143; carbamazepine, monitoring (A) 1216; cimetidine (L) 1007; cyclosporine (L) 1007; quinidine, immune globulin (CR) 693

Thyroid drugs, homeopathic, therapeutic potential (SR) 26

Time studies, ranitidine admixtures (SR) 590

Tobramycin, dosing, obesity (L) 100; pharmacokinetics, volume of distribution, pediatrics (PED) 273; with azlocillin, compared with ciprofloxacin, cystic fibrosis (RPR) 12

Tocainide, myotonic dystrophy (DIAS) 69

Tolmetin, gastric bleeding, cimetidine (TC) 955, misoprostol (TC) 955

Townsend, Raymond J., Director, Medical Marketing, Glaxo, Inc. (NC) 916

Toxicity, amiodarone, postmarketing surveillance (PEP) 1001; carbamazepine, postoperative, myocardial infarction (CR) 822; cholinergic, bethanechol (L) 327; clonidine, transdermal (PED) 1191; digitalis, digoxin immune fab (A) 991; meperidine (L) 891; phenytoin, AIDS (CR) 698; verapamil (SR) 705

Tranquilizers, drug utilization (PEP) 878

Trauma, hypertension, tachycardia, labetalol (CR) 235; post-, seizures, prophylaxis (CC) 277

Tretinoin, with minoxidil, baldness (DIAS) 43

Triazolam, amnesia, delirium, withdrawal, review (TC) 390

Trifluoperazine, seizures (A) 604

Trihexyphenidyl hydrochloride, abuse (DIAS) 40

Trimethoprim, with sulfamethoxazole, colonization resistance (A) 64, compared with cefixime (FF) 492, exfoliative dermatitis (CR) 140, interaction, glipizide (SR) 250, zidovudine (FF) 758, left shift, differential (L) 782

Tryptophan, eosinophilia myalgia syndrome (L) 1009

Tuberculin skin tests, interaction, BCG vaccine, review (DIR) 186, live-virus vaccines, review (DIR) 187

Tuberculosis, incidence (NC) 566; new therapy needed (O) 883

Tubing, feeding, irrigation, carbonated beverages (DIAS) 840

U–Z

Ulcers, stress, pathogenesis (S) S5; prophylaxis (S) S6

United Kingdom, prescribing, elderly (G) 533

United States Pharmacopeial Convention, 1990 quinquennial meeting, controversial resolutions (NC) 566

Ureidopenicillins, compared with ciprofloxacin, bone infections (RPR) 13

USPHS–CDC News (NC), AIDS Map, 1248; Asthma—United States, 1980–1987, 914; Availability of Primaquine Phosphate, 914; Changes in Measles Vaccination Policy, 224; Comorbidity of Chronic Conditions and Disability in Older People, 117; FDA Approves *Haemophilus b* Conjugate Vaccine, 1152; Meningococcal Vaccine in Single-Dose Vials, 1248; National AIDS Information Clearinghouse, 1152; Perinatal Mortality and Congenital Malformations in Infants Born to Women with Insulin-Dependent Diabetes Mellitus, 1034; Plasmid-Mediated Antimicrobial Resistance in *Neisseria gonorrhoeae*, 668; Revised Dosing Regimen for Mefloquine, 1034; Standards for Adult Immunization Practice, 1248; Tetanus—1987–88, 452; Update: Tuberculosis Incidence, 566; Vaccine Adverse Event Reporting System, 1248

Vaccines, *Haemophilus b* conjugate, approved (NC) 1152; interactions, vaccines, immunoglobulin, drugs, review (DIR) 67; live virus, interaction, histoplasmin, review (DIR) 187, interactions, tuberculin skin tests, review (DIR) 187

Valproic acid, bipolar disorder (DIAS) 257; excipients, diarrhea (SR) 832

Vancomycin, coagulase-negative staphylococci (A) 717; compared with ciprofloxacin, bone infections (RPR) 13; exfoliative dermatitis (CR) 369; *Staphylococcus epidermidis*, methicillin-resistant *Staphylococcus conjunctivitis* (CR) 1050; with colestipol, pseudomembranous colitis (DIAS) 70

Varicella vaccine, interactions, review (DIR) 71

Ventilation, mechanical, classification (CC) 961, complications (CC) 966, indications (CC) 963, review (CC) 959

Verapamil, compared with nitrendipine (FF) 170; nocturnal leg cramps (DIAS) 599; schizophrenia (DIAS) 838; sustained-release, overdose (SR) 705

VIP News (NC), Benet, Leslie Z., 118; Campbell, R. Keith, 346, 1248; Chrischilles, Elizabeth A., 566; Dasta, Joseph F., 452; Doering, Paul L., 452; Gerbino, Philip P., 346; Jones, Mark E., 566; Nahata, Milap C., 118; Oddis, Joseph A., 346; Robinson, J. Daniel, 118; Rybak, Michael J., 566; Schentag, Jerome J., 346; Stringer, Kathleen A., 118; Wertheimer, Albert I., 346

Warfarin, interaction, ciprofloxacin (SR) 27, fluconazole (SR) 1177; short-bowel syndrome (CR) 585

Warts, bleomycin (DIAS) 952

Weight, astemizole, no gain (RPR) 682

Wertheimer, Albert I., Dean of Pharmacy, Philadelphia College of Pharmacy and Science, 346

Yellow fever vaccine, interactions, review (DIR) 68

Zidovudine, adverse reactions (FF) 757; clinical studies (FF) 755; interaction, interferon alfa, review (DIR) 189, review (FF) 758; pharmacokinetics (FF) 754; review (FF) 754

AUTHOR INDEX

A–B

Abadin, Jose A. (coauthor) see **Torello, Jaume,** 543

Abate, Marie A. (author) book review, 209; (author) Effect of Naproxen and Sulindac on Blood Pressure Response to Atenolol (RPR) 810; (coauthor) see **Ross, Johnanne,** 1050

Abel, Steven R. (coauthor) see **Mueller, Bruce A.,** 422

Achumba, Judy I. (coauthor) see **Ette, Ene I.,** 426

Ackerman, Bruce H. (coauthor) see **Olsen, Keith M.,** 1159

Ala-Kokko, Tero I. (coauthor) see **Larijani, Ghassem E.,** 328

Albrecht, Lisa M. (coauthor) see **Bailey, Elaine M.,** 714

Alexander, Bruce (coauthor) see **Cleary, John D.,** 1117; (coauthor) see **Sobotka, Jenelle L.,** 1166, 1214

Alldredge, Brian K. (coauthor) see **Chan, John,** 246

Allen, Nancy M. (author) Treatment of Digitalis Intoxication with Emphasis on the Clinical Use of Digoxin Immune Fab (A) 991

Amato, Mary Gaul (author) book review, 648, 1126

Amodio, Maria I. (author) Development of Acute Gout Secondary to Pyrazinamide in a Patient Without a Prior History of Gout (L) 1115

Anderson, Brian A. (coauthor) see **Rauser, Elma H.,** 207

Andrews, Elizabeth B. (coauthor) see **Johnson, Richard E.,** 624

Angaran, David M. (coauthor) see **Naylor-Shepherd, Michele F.,** 1195

Angell, Reginald S. (author) Tryptophan and Eosinophilia Myalgia Syndrome (L) 1009

Ani, Faisal M. (coauthor) see **Tarifi, Hashem A.,** 769

Aranegui, Pedro (author) Danazol for Evan's Syndrome Due to SLE (L) 641

Araujo, Oscar E. (author) Griseofulvin: A New Look at an Old Drug (A) 851

Arbogast, James G. (coauthor) see **Ponte, Charles D.,** 140

Arellano, Felix (coauthor) see **Soto, Javier,** 1115

Ariano, Robert E. (coauthor) see **Rauser, Elma H.,** 207

Arnon, Ron (coauthor) see **Caraco, Yoseph,** 327

Assad, Abdulla M. (coauthor) see **Tarifi, Hashem A.,** 769

Atra, Edgar (author) Flurbiprofen Versus Diclofenac for the Treatment of Osteoarthritis of the Knee (RPR) 920

Aull, Larry D. (author) book review, 1014; (author) Heparin-Induced Hyperkalemia (CR) 244

Avila, Pilar (coauthor) see **Ibanez, Luisa,** 786

Avisar, Rahamim (author) Norfloxacin Ophthalmic Versus Chloramphenicol in Bacterial Conjunctivitis and Blepharoconjunctivitis (L) 640

Bahal, Neeta (coauthor) see **Gonzalez, Edgar R.,** 1064

Bailey, Elaine M. (author) Coagulase-Negative Staphylococci: Incidence, Pathogenicity, and Treatment in the 1990s (A) 714

Bailey, Robert T., Jr. (author) Influence of Dissolution Rate and pH of Oral Medications on Drug-Induced Esophageal Injury (RPR) 571

Baker, Danial E. (author) book review, 1125

Baldwin, Charlene M. (author) A Case of Lisinopril-Induced Lithium Toxicity (SR) 946

Ballard, Craig (author) Antibiotic Prophylaxis in Dental Procedures (DIAS) 41

Balmer, Carol McManus (author) Clinical Use of Biologic Response Modifiers in Cancer Treatment: An Overview Part I: The Interferons (DSP) 761

Barbarash, Rick A. (author) Mechanical Ventilation (CC) 959

Barbour, Marilyn McFarland (coauthor) see **West, Dennis P.,** 464

Barker, David B. (author) The Potential for Mental Status Changes Associated with Systemic Absorption of Anticholinergic Ophthalmic Medications: Concerns in the Elderly (DIR) 847

Barker, Donald E. (coauthor) see **Goldsmith, Tracey L.,** 235

Barkin, Robert L. (author) Comment: Dexamethasone Binding (L) 1010; (coauthor) see **Leikin, Jerrold B.,** 781

Barlow, Jared C. (coauthor) see **Maponga, Charles,** 123

Barone, Joseph A. (author) The Generic Drug Scandal and Its Implications for Pharmacy Professionals (L) 98; (coauthor) see **Raia, John J., Jr.,** 506

Barreuther, Alan D. (author) Comment: Hydroxyzine for the Potentiation of Pain Relief (L) 1123

Baskin, Laurence S. (coauthor) see **Chan, John,** 246

Beam, Thomas R., Jr. (coauthor) see **Katz, Paul R.,** 783

Bednarczyk, Edward M. (author) Hyperventilation-Induced Reduction in Cerebral Blood Flow: Assessment by Positron Emission Tomography (RPR) 456

Beijnen, Jos H. (author) Chemical Stability of Suramin in Commonly Used Infusion Fluids (SR) 1056

Bengualid, Victoria (coauthor) see **Amodio, Maria I.,** 1115

Benjamin, Stanley B. (author) Sclerotherapy for Esophageal Varices (S) S47

Bennett, John R. (coauthor) see **Rodenberg, Howard D.,** 358

Bentley, David W. (coauthor) see **Karki, Shyam D.,** 595

Bertch, Karen E. (author) book review, 552

Bess, David T. (coauthor) see **Mickle, Timothy R.,** 927

Bhopal, Jaswant Singh (author) Comment: Phenothiazines and Hirsutism (L) 1124

Billeter, Marianne (author) book review, 1013

Birge, Stanley (coauthor) see **Lackner, Thomas E.,** 29

Bitter, Istvan (author) book review, 790

Black, Douglas J. (coauthor) see **Seaton, Terry L.,** 1177

Black, Jimmy T. (coauthor) see **Ponte, Charles D.,** 1118

Blackburn, Jim L. (author) The Saskatchewan Program for Rational Drug Therapy: Effects on Utilization of Mood-Modifying Drugs (PEP) 878

Bloom, Arnon (coauthor) see **Burstein, Moshe,** 206

Blum, A.L. (coauthor) see **Dent, John,** 1226

Blumberg, Emily A. (author) Cerebellar Syndrome Caused by Isoniazid (SR) 829

Bolwerk, Clemens J. (coauthor) see **de Flines, Egbert W.,** 783

Bonavina, Luigi (coauthor) see **Bailey, Robert T., Jr.,** 571

Bond, William S. (coauthor) see **Boyce, Eric G.,** 19

Bonfiglio, Mark F. (author) High-Dose Phenylephrine Infusion in the Hemodynamic Support of Septic Shock (CR) 936

Bootman, J. Lyle (coeditor) see **McGhan, William F.,** 82, 304, 422

Borchardt-Phelps, Pamela K. (author) Amphotericin B Dilution (DIAS) 597

Bosso, John A. (author) Clindamycin Stability (L) 1008

Bottorff, Michael B. (author) book review, 1013

Boucher, Bradley A. (coauthor) see **Kuhl, David A.,** 277

Bourghol, Amer (author) Cimetidine-Associated Thrombocytopenia (L) 1007

Boyce, Eric G. (author) Persistent Metronidazole-Induced Peripheral Neuropathy (CR) 19

Bozigian, Haig P. (coauthor) see **Davis, Robin L.,** 1040

Brenner, Sarah (author) Ectropion: An Adverse Effect of Etretinate Therapy for Psoriasis (L) 1007

Brereton, William F. (coauthor) see **Ray, James B.,** 693

Brierton, Dennis (author) Warning: Acetaminophen and Aprolide Both Labeled Apronal (L) 1232

Britton, Mark L. (coauthor) see **Letassy, Nancy A.,** 1204

Brouwer, Kim L.R. (coauthor) see **Hussey, Elizabeth K.,** 678

Brown, Bruce L. (coauthor) see **Atra, Edgar,** 920

Brownell, Lisa (coauthor) see **Tankanow, Roberta M.,** 382

Bunz, Donna M. (author) Simple Ways to Promote Cost Containment (L) 546

Burke, John P. (coauthor) see **Evans, R. Scott,** 351

Burnett, Richard J. (author) Severe Hypomagnesemia Induced by Pentamidine (CR) 239

Burstein, Moshe (author) Nonthrombocytopenic Purpura Induced by Cefoxitin (L) 206

Byerly, Wesley G. (coauthor) see **Raia, John J., Jr.,** 506

C–D

Caldwell, Felix L. (coauthor) see **Mickle, Timothy R.,** 927

Calvert, John F. (author) Authors' Reply: Neurologic Toxicity Related to Ciprofloxacin (L) 892; (coauthor) see **Schwartz, Marla T.,** 138

Campbell, James R. (coauthor) see **Maloley, Pierre A.,** 143

Cano, Santiago M. (coauthor) see **Montoro, Jose B.,** 439

Caraco, Yoseph (author) Bethanechol-Induced Cholinergic Toxicity in Diabetic Neuropathy (L) 327

Caravagio, Ciro (coauthor) see **Leggett, Nancy J.,** 489

Cardoni, Alex A. (coauthor) see **Fish, Susan S.,** 891

Carnes, Cynthia A. (author) Moricizine: A Novel Antiarrhythmic Agent (FF) 745

Carre, M. Carmen (coauthor) see **Sanahuja, Jaime,** 361

Carson, Deborah Stier (coauthor) see **Peters, Mark D., II,** 599

Carter, Barry L. (author) A Structure for Pharmacy Specialization (E) 1113
Carter, Charles A. (author) book review, 894
Casdorph, Diane L. (author) Topical Aminocaproic Acid in Hemophiliac Patients Undergoing Dental Extraction (DIAS) 160
Catania, Patrick N. (coauthor) see **Ibrahim, Osama M.**, 817
Cavell, Richard M. (coauthor) see **Yamreudeewong, Weeranuj**, 887
Celum, Connie L. (coauthor) see **Seaton, Terry L.**, 1177
Cetnarowski-Cropp, Anne B. (coauthor) see **Csako, Gyorgy A.**, 26
Chacon, Jose R. (coauthor) see **Kortabarria, Rafael P.**, 708
Chan, Gary L.C. (author) Author's Reply: Nephrotoxicity from Once-Daily Dosing of Gentamicin (L) 1119
Chan, John (author) Perphenazine-Induced Priapism (CR) 246
Chan, Suzanna (author) Bleomycin Treatment of Warts (DIAS) 952
Chandler, Mary H.H. (coauthor) see **Toler, Steven M.**, 698
Chao, Helen (coauthor) see **Aull, Larry D.**, 244
Chapman, Jeff (coauthor) see **Heiselman, Darell E.**, 1163
Chapman, Stanley W. (coauthor) see **Cleary, John D.**, 148
Cheng, Shih-Chuan (coauthor) see **Bailey, Robert T., Jr.**, 571
Cherniwchan, Darin P. (coauthor) see **Martins, A. Melanie**, 887
Child, Jeffrey A. (coauthor) see **Pane, Fred J.**, 439
Chow, Moses S.S. (coauthor) see **Colucci, Robert D.**, 99
Choy, Fred N. (author) Experience with Home Aerosolized Pentamidine Treatment in Patients with AIDS (SR) 592
Cipolle, Robert J. (coauthor) see **Strand, Linda M.**, 1093
Clasener, Henk A.L. (coauthor) see **Vollaard, Ernst J.**, 60
Classen, David C. (coauthor) see **Evans, R. Scott**, 351
Cleary, John D. (author) Blind Versus Nonblind Review: A Reevaluation of Selected Medical Journals (SR) 1117; (author) Comment: Neurologic Toxicity Related to Ciprofloxacin (L) 891; (author) Imidazoles and Triazoles in Antifungal Therapy (DSP) 148
Cluxton, Robert J., Jr. (author) book review, 648
Cohen, Louise Glassner (author) book review, 648; (coauthor) see **Fish, Susan S.**, 891
Cohen, Ohad (coauthor) see **Mor, Felix**, 135
Colaizzi, John L. (coauthor) see **Barone, Joseph A.**, 98
Cold, Julie A. (author) Correction: Seizure Activity Associated with Antipsychotic Therapy (L) 1012; (author) Seizure Activity Associated with Antipsychotic Therapy (A) 601; (coauthor) see **Angell, Reginald S.**, 1009
Coll, Joaquin (coauthor) see **Pedro-Botet, Juan**, 438
Coll, Pere (coauthor) see **Rello, Jordi**, 1233
Colomina, Pedro (author) Authors' Reply: Agranulocytosis Caused by Diclofenac (L) 786
Colucci, Robert D. (author) Esmolol for the Treatment of Ventricular Tachycardia (L) 99
Conklin, Lizabeth C. (coauthor) see **Sesin, G. Paul**, 97
Conner, Dale P. (coauthor) see **Cummings, Doyle M.**, 229, 1010
Constance, Thomas D. (coauthor) see **Bailey, Elaine M.**, 714
Cook, Brian L. (coauthor) see **Sobotka, Jenelle L.**, 1166, 1214
Cookson, Eileen T. (coauthor) see **Boyce, Eric G.**, 19
Cooper, Gary R. (coauthor) see **Krick, Stacie E.**, 705
Cooper, Robert G. (coauthor) see **Tully, Mary P.**, 1234
Copa, Alan K. (author) Teaching and Education of Future Clinicians (L) 642
Copley, John B. (coauthor) see **Southwood, Robin L.**, 855
Corbera, Gaspar (coauthor) see **Sanahuja, Jaime**, 361
Corey, Paul N. (coauthor) see **Ferguson, Joyce Ann**, 310
Corliss, Don A. (coauthor) see **Forstrom, Margo J.**, 304
Cover, Darra L. (author) Ciprofloxacin Penetration into Human Breast Milk: A Case Report (SR) 703; (coauthor) see **Mueller, Bruce A.**, 1122
Coy, Kevin (coauthor) see **Aull, Larry D.**, 244
Coyle, James D. (coauthor) see **Carnes, Cynthia A.**, 745
Crabbe, Sarah J. (coauthor) see **Wilson, Douglas E.**, 1117
Crane, Vicki S. (author) Pharmacoeconomics: Therapeutic and Economic Considerations in Treating the Critically Ill Patient (S) S24
Crismon, M. Lynn (author) book review, 103; (coauthor) see **Wasan, Suman M.**, 889
Crocker, Kathleen S. (coauthor) see **Choy, Fred N.**, 592
Csako, Gyorgy A. (author) Therapeutic Potential of Two Over-the-Counter Thyroid Hormone Preparations (SR) 26; (author) Characterization of Dexamethasone Binding in Normal and Uremic Human Serum (RPR) 229
Curry, Stephen H. (author) book review, 894
Cwik, Michael J. (coauthor) see **West, Dennis P.**, 464
Dahl, Jeffrey R. (author) Comparative Bioavailability Characteristics of Commercial Quinidine Polygalacturonate and Sulfate Tablets (RPR) 685
Dahl, Stephen L. (author) book review, 895
Dales, Robert E. (coauthor) see **Fong, Samantha L.C.**, 689
D'Alessandri, Robert (coauthor) see **Abate, Marie A.**, 810
Dapas, Frances (coauthor) see **Stemhagen, Annette**, 786
Dasta, Joseph F. (author) Computers in Critical Care: Opportunities and Challenges (CC) 1084; (author) Norepinephrine in Septic Shock: Renewed Interest in an Old Drug (CC) 153; (author) SCAMC: A Meeting of the "Computer" Minds (L) 888; (coauthor) see **Bonfiglio, Mark F.**, 936; (editor) Critical Care Therapeutics, 153, 277, 959, 1084, 1195
Dattola, Richard K. (coauthor) see **Ponte, Charles D., 140**
Davis, Robin L. (author) Pharmacokinetics of Ranitidine in Morbidly Obese Women (RPR) 1040
Davis, Sharon K. (coauthor) see **Nicolau, David P.**, 840; (coauthor) see **Whelan, Anne Marie**, 598
De Abajo, Francisco J. (coauthor) see **Ibanez, Luisa**, 786
de Bolos, Josep Maria Arnau (author) Comment: Albumin Use in Hospitals (L) 101
de Flines, Egbert W. (author) Abnormal Metabolism of Phenylbutazone after Overdosage (L) 783
DeJong, Douglas J. (author) Possible Cyclosporine-Associated Thrombocytopenia (L) 1007
Dellinger, R. Phillip (author) Pathophysiology, Monitoring, and Management of the Ventilator-Dependent Patient: Considerations for Drug Therapy, Emphasis on Stress Ulcer Prophylaxis (S) S8
Delorme, Michael A. (author) Prescribing and Dispensing Practices for Oral Iron Tablets: A Canadian Experience (IR) 874
DeMeester, Tom R. (coauthor) see **Bailey, Robert T., Jr.**, 571
Denig, Petra (author) Impact of a Drug Bulletin on the Knowledge, Perception of Drug Utility, and Prescribing Behavior of Physicians (IR) 87
Dent, John (author) Current and Future Drugs for Acid-Peptic Disease: A Plethora of Opinions and Possible Mechanisms of Action (O) 1226
Depka, Clifford H. (coauthor) see **Drinka, Paul J.**, 381
DeSimone, Cheryl A. (coauthor) see **Larijani, Ghassem E.**, 328
DeSimone, Edward M., II (author) book review, 647
Deterville, Richard J. (coauthor) see **Drinka, Paul J.**, 381
D'Hoore, William (author) Lorazepam and Sleep Quality (L) 325
Dickinson, David G. (coauthor) see **Tankanow, Roberta M.**, 382
Dimand, Robert J. (author) Use of H_2-Receptor Antagonists in Children (S) S42
Do, Thuy Minh (author) ACE Inhibitor-Induced Cough (DIAS) 1059
Dobbs, Joel H. (author) book review, 1015, 1239
Dobmeier, Michael E. (coauthor) see **Johnson, June Felice**, 250
Doering, Paul L. (author) book review, 443; (author) Drugs for Treatment of Vulvovaginal Candidiasis: Comparative Efficacy of Agents and Regimens (DSP) 1078
Dominguez, Francisco J. (coauthor) see **Kortabarria, Rafael P.**, 708
Dong, Betty J. (coauthor) see **Pon, Doreen**, 951
Donn, Karl H. (coauthor) see **Hussey, Elizabeth K.**, 678
Downey, F. Winanne (coauthor) see **Blackburn, Jim L.**, 878
Drea, Edward J. (author) Author's Reply: Cimetidine-Induced Bradycardia (L) 1124; (author) Authors' Reply: Incidence of Adverse Reactions Caused by Contrast Media (L) 548; (author) Cimetidine-Associated Adverse Reaction (CR) 581
Dretler, Robin H. (coauthor) see **Job, Martin L.**, 467
Drinka, Paul J. (author) Transition from Lanoxin Capsules to Lanoxin Tablets in the Debilitated Elderly (SR) 381
Driscoll, David F. (author) Clinical Issues Regarding the Use of Total Nutrient Admixtures (A) 296
Driver, Albert G. (author) Intravenous Streptomycin (CR) 826
Dukes, George E. (author) Comment: Pharmacotherapy and Certification (L) 644; (coauthor) see **Hussey, Elizabeth K.**, 678; (coauthor) see **Lampkin, Thomas A.**, 393
Dunham, Gary D. (coauthor) see **Allen, Nancy M.**, 991
Duran, Jose A. (coauthor) see **Kortabarria, Rafael P.**, 708; (coauthor) see **Torello, Jaume**, 543

E–F

Earnest, David L. (author) Controlling Gastric pH: the Impact of Newer Agents on the Critically Ill Patient (S) S31
Edwards, David J. (author) book review, 102
Ehrenpreis, Eli D. (coauthor) see **Leikin, Jerrold B.**, 781
El Amrani, Abdelghani (coauthor) see **Aranegui, Pedro**, 641
Elliott, David P. (author) An Assessment of the Drug Therapy Education Preferences of an Interdisciplinary Group Interested in the Elderly (RPR) 460; (author) Preventing Upper Gastrointestinal Bleeding in Patients Receiving Nonsteroidal Antiinflammatory Drugs (TC) 954
Ellison, Mark J. (author) Lack of Weight Gain Associated with Short-Term Astemizole Treatment (RPR) 682
Elswick, R.K., Jr. (coauthor) see **Gonzalez, Edgar R.**, 590
Eng, Howard J. (author) Assessment of the Florida Pharmacist Self-Care Consultant Law Using Patient Profile and Prescription Audit Methods (RPR) 931
Engle, Janet P. (coauthor) see **Solimando, Dominic A., Jr.**, 1011
Epstein, Sara (coauthor) see **Skowron, Diane M.**, 1008
Ertel, Inta J. (coauthor) see **Tankanow, Roberta M.**, 382
Escobar, Camilo (coauthor) see **Montoro, Jose B.**, 439
Ette, Ene I. (author) Ivermectin: A Long-Acting Microfilaricidal Agent (IR) 426
Evans, R. Scott (author) Reducing the Duration of Prophylactic Antibiotic Use Through Computer Monitoring of Surgical Patients (RPR) 351
Eward, Ann M. (author) book review, 1237
Fagiolino, Pietro L. (author) Estimating Pharmacokinetic Values (L) 208
Farr, Glen E. (coauthor) see **Mickle, Timothy R.**, 927
Fater, C. Patricia (coauthor) see **Voytovich, Robert M.**, 100
Fazio, Anthony (coauthor) see **Janda, Sue M.**, 545, 1120
Fekete, Thomas (author) Aztreonam Adverse Reactions (L) 438
Ferguson, Joyce Ann (author) Adjusting for Clustering in Survey Research (PEP) 310
Ferguson, Roger K. (coauthor) see **Cummings, Doyle M.**, 229, 1010
Fiedler, Virginia C. (coauthor) see **West, Dennis P.**, 464
Fischer, James H. (coauthor) see **West, Dennis P.**, 464
Fish, Susan S. (author) Authors' Reply: Clinical Education in Rhode Island (L) 891
Fitzsimons, Bartholemew M. (coauthor) see **Murphy, JoAnn M., 1001**
Flancbaum, Louis (coauthor) see **Bonfiglio, Mark F.**, 936
Fletcher, Courtney V. (author) book review, 1237
Flowers, Franklin P. (coauthor) see **Araujo, Oscar E.**, 851
Fong, Michael (author) Captopril in Diabetic Nephropathy (DIAS) 260
Fong, Samantha L.C. (author) Compliance Among Adults with Cystic Fibrosis (RPR) 689
Forrence, Elizabeth A. (author) Vancomycin-Associated Exfoliative Dermatitis (CR) 369
Forstrom, Margo J. (author) Effect of a Clinical Pharmacist Program on the Cost of Hypertension Treatment in an HMO Family Practice Clinic (PEC) 304
Fraker, Theodore D., Jr. (coauthor) see **Mauro, Vincent F.**, 252
Friedman, Barry (coauthor) see **Barreuther, Alan D.**, 1123
Frighetto, Luciana (coauthor) see **Bunz, Donna M.**, 546
Froemming, Judy H. (coauthor) see **Cold, Julie A.**, 601
Fuhs, David W. (coauthor) see **Naylor-Shepherd, Michele F.**, 1195
Fulton, Bret (author) Comment: Ciprofloxacin Excretion into Breast Milk (L) 1122

G–H

Gait, John E. (author) Hemolytic Reactions to Nitrofurantoin in Patients with Glucose-6-Phosphate Dehydrogenase Deficiency: Theory and Practice (DIR) 1210
Gal, Peter (coauthor) see **Maloley, Pierre A.**, 326
Garau, Javier (coauthor) see **Sanahuja, Jaime**, 361
Garcia, Sonia (coauthor) see **Colomina, Pedro**, 786
Garcia-Cases, Carles (coauthor) see **Rello, Jordi**, 544
Gardner, Martha L. (author) Sodium Loading Treatment for Amphotericin B-Induced Nephrotoxicity (CR) 940
Gardner, Reed M. (coauthor) see **Evans, R. Scott**, 351
Garner, Andrew (coauthor) see **Dent, John**, 1226
Garrelts, James C. (author) Fluosol: An Oxygen-Delivery Fluid for Use in Percutaneous Transluminal Coronary Angioplasty (FF) 1105
Garrison, Mark W. (author) Aminoglycosides: Another Perspective (DSP) 267
Garson, Michelle (coauthor) see **Lysy, Joseph**, 782
Gaurano, Valerie (coauthor) see **Sramek, John J.**, 7
Geraets, Douglas R. (coauthor) see **Wirebaugh, Stewart R.**, 22, 1046
Gil, Ramon A. (coauthor) see **Blumberg, Emily A.**, 829
Giner, Pilar (coauthor) see **Aranegui, Pedro**, 641
Glazier, Howard S. (author) Potentiation of Pain Relief with Hydroxyzine: A Therapeutic Myth? (TC) 484
Glick, Marcia (author) Antibiotic Prophylaxis in Cesarean Section (TC) 841
Godley, Paul J. (coauthor) see **Gardner, Martha L.**, 940; (coauthor) see **Ponte, Charles D.**, 1118
Godwin, Jeffrey E. (coauthor) see **Barbarash, Rick A.**, 959
Goldman, Morton P. (author) Ciprofloxacin Drug Utilization Review and Prospective Drug Use Evaluation (PEC) 82; (coauthor) see **Forrence, Elizabeth A.**, 369
Goldsmith, Tracey L. (author) Prolonged Labetalol Infusion for Management of Severe Hypertension and Tachycardia in a Critically Ill Trauma Patient (CR) 235
Goldspiel, Barry R. (author) Flutamide: An Antiandrogen for Advanced Prostate Cancer (FF) 616
Gonzalez, Edgar R. (author) Gastroesophageal Reflux and Respiratory Symptoms: Is There an Association? Proposed Mechanisms and Treatment (TC) 1064; (author) Pathophysiologic Changes in the Critically Ill Patient: Risk Factors for Ulceration and Altered Drug Metabolism (S) S5; (author) Time-Motion Study of Intravenous Ranitidine Admixtures (SR) 590
Goto, Mitsuyoshi (coauthor) see **Ohkita, Chieko**, 814
Gotz, Vincent P. (author) book review, 210
Grabenstein, John D. (author) Drug Interactions Involving Immunologic Agents: Part 2. Immunodiagnostic and Other Immunologic Drug Interactions (DIR) 186; (author) Drug Interactions Involving Immunologic Agents: Part I. Vaccine–Vaccine, Vaccine–Immunoglobulin, and Vaccine–Drug Interactions (DIR) 67
Gradon, Jeremy D. (author) Massive Hepatic Enlargement with Fatty Change Associated with Ketoconazole (SR) 1175
Grasela, Thaddeus H., Jr. (author) A Nationwide Survey of Antibiotic Prescribing Patterns and Clinical Outcomes in Patients with Bacterial Pneumonia (PEP) 1220
Gratz, Irwin (coauthor) see **Larijani, Ghassem E.**, 647
Grauer, Ken (coauthor) see **Krick, Stacie E.**, 705
Graves, Nina M. (author) book review, 1125
Graves, Terri (author) Ondansetron: a New Entity in Emesis Control (S) S51
Green, Jeffrey A. (coauthor) see **Bednarczyk, Edward M.**, 456
Gregory, James S. (coauthor) see **Bonfiglio, Mark F.**, 936
Griener, James C. (coauthor) see **Lamp, Kenneth C.**, 1010

Grigas, Scott E. (coauthor) see **Sesin, G. Paul,** 97
Guay, David R.P. (author) Oral Fluoroquinolone Versus Mono- or Combination Parenteral Therapy in the Management of Bacterial Infections: A Critical Appraisal (RPR) 11
Guglielmo, B. Joseph (coauthor) see **Glick, Marcia,** 841; (coauthor) see **Hebert, Mary F.,** 735
Gums, John G. (coauthor) see **Krick, Stacie E.,** 705; (coauthor) see **Rey, Aixa M.,** 1116; (coauthor) see **Skluth, Hilary A.,** 52
Gundlach, Catherine A. (coauthor) see **Fish, Susan S.,** 891
Gupta, Sarita (coauthor) see **Bunz, Donna M.,** 546
Gurgui, Merce (coauthor) see **Rello, Jordi,** 1233
Guthrie, Sally K. (author) Pharmacologic Interventions for the Treatment of Opioid Dependence and Withdrawal (A) 721
Gutierrez, Luz M. (author) Spanish-Language Pharmacists (L) 101
Gutierrez, Mary A. (coauthor) see **Skowron, Diane M.,** 1008
Gwadry-Sridhar, Femida H. (coauthor) see **Delorme, Michael A.,** 874
Haaijer-Ruskamp, Flora M. (coauthor) see **Denig, Petra,** 87
Hak, Lawrence J. (coauthor) see **Hussey, Elizabeth K.,** 678; (coauthor) see **Lampkin, Thomas A.,** 393
Halperin, John J. (author) book review, 1014
Hamilton, Don P. (coauthor) see **Martins, A. Melanie,** 887
Hampton, Edward M. (coauthor) see **Smith, Curtis L.,** 1185; (coauthor) see **Wright, Patricia Small,** 822
Hansten, Philip D. (author) Overview of the Safety Profile of the H_2-Receptor Antagonists (S) S38
Harper-Brown, Deborah (coauthor) see **Leikin, Jerrold B.,** 781
Harris, Jennifer Meyer (author) Clonidine Patch Toxicity (PED) 1191
Hart, Linda L. (coauthor) see **Do, Thuy Minh,** 1059; (coauthor) see **Fong, Michael,** 260; (coauthor) see **Hendel, Diana L.,** 158; (coauthor) see **Hong, Diann,** 1062; (coauthor) see **Jew, Lyle J.,** 711; (coauthor) see **Kelly, Janet L.,** 157; (coauthor) see **Lee, Connie R.,** 712; (coauthor) see **London-Wong, Diane M.,** 43; (coauthor) see **Lorimer, Dorothea,** 1060; (coauthor) see **Ma, Christine B.,** 480; (coauthor) see **Ramoran, Nelson,** 257; (coauthor) see **Teshima, Jeff Y.,** 385; (coauthor) see **Womack, Patricia L.,** 710; (editor) DIAS Rounds, 40, 157, 257, 385, 475, 597, 710, 837, 951, 1059, 1179
Hartshorn, Edward A. (editor) Drug Interactions and Reactions Update, 67, 186, 286, 847, 982, 1210
Hartzema, Abraham G. (editor) Pharmacoepidemiology, 176, 624, 878, 1001, 1220
Harvit, Pamela A. (coauthor) see **Elliott, David P.,** 460
Hatoum, Hind T. (coauthor) see **Hutchinson, Richard A.,** 633
Hazas, Julia (coauthor) see **Soto, Javier,** 1115
Healy, Daniel P. (coauthor) see **Lysy, Joseph,** 782
Hebert, Mary F. (author) What is the Clinical Role of Aerosolized Ribavirin? (TC) 735
Heiselman, Darell E. (author) Hemodynamic Status During Famotidine Infusion (RPR) 1163
Henann, Neil E. (coauthor) see **Janda, Sue M.,** 545, 1120; (coauthor) see **Yamreudeewong, Weeranuj,** 887
Hendel, Diana L. (author) Interferon in Multiple Sclerosis (DIAS) 158
Herrera, John M. (coauthor) see **Sramek, John J.,** 7
Heyman, Ayelet (coauthor) see **Burstein, Moshe,** 206
Hidalgo, Hanneli A. (author) Anticholinergic Drug Abuse (DIAS) 40
Higuchi, Shun (coauthor) see **Ieiri, Ichiro,** 629
Hodak, Emmilia (coauthor) see **Mimouni, Aviva,** 947
Hoffman, Dennis M. (coauthor) see **MacArthur, Robert B.,** 788
Hoffman, Nannette B. (author) Dexamethasone Aerosol Use in an Asthmatic Nursing Home Patient with Parkinson's Disease and Dementia (SR) 707
Holden, J.M.C. (coauthor) see **Karki, Shyam D.,** 202
Holland, Eileen G. (coauthor) see **Kumpf, Vanessa J.,** 162
Hong, Diann (author) Topical Minoxidil for Hair Loss in Women (DIAS) 1062
Horenblas, Simon (coauthor) see **Beijnen, Jos H.,** 1056
Horner, Ronnie D. (coauthor) see **Ellison, Mark J.,** 682
Hruska, Barbara M. (coauthor) see **Gonzalez, Edgar R.,** 590
Hume, Anne L. (author) Severe Hyponatremia: An Association with Lisinopril? (CR) 1169
Hundart, Orit (coauthor) see **Avisar, Rahamim,** 640
Hurst, Agneta K. (author) book review, 1012
Hussey, Elizabeth K. (author) Correlation of Delayed Peak Concentration with Infusion-Site Irritation Following Diazepam Administration (RPR) 678
Hutchinson, Richard A. (author) Inconsistencies in the Drug Use Process (A) 633
Hutson, Paul R. (coauthor) see **Mutch, Rebecca S.,** 885
Hutton, Gary D. (coauthor) see **Shaefer, Mark S.,** 472

I–L

Ibanez, Luisa (author) Comment: Agranulocytosis Caused by Diclofenac? (L) 786
Iberti, Thomas J. (author) Hemodynamic Effects of H_2-Receptor Antagonists (S) S35
Ibrahim, Osama M. (author) Outcome of Cholesterol Screening in a Community Pharmacy (RPR) 817
Ieiri, Ichiro (author) Therapeutic Drug Monitoring Services in Kyushu University Hospital in Japan (IR) 629
Inwood, Martin J. (coauthor) see **Delorme, Michael A.,** 874
Jack, Brian W. (coauthor) see **Hume, Anne L.,** 1169
Jackson, Eric A. (author) book review, 789
Jaeger, Judith (coauthor) see **Zito, Julie Magno,** 176
Janda, Sue M. (author) Authors' Reply: IV Alcohol in Prevention of Delirium Tremens (L) 1120; (author) IV Alcohol in Prevention of Delirium Tremens (L) 545
Jané, Francesc (coauthor) see **Rello, Jordi,** 544
Janelle, Andrea (coauthor) see **Sesin, G. Paul,** 206
Jankel, Charlotte A. (author) Detecting Drug Interactions: A Review of the Literature (DIR) 982
Jayson, Malcolm I.V. (coauthor) see **Tully, Mary P.,** 1234
Jermain, Donna M. (coauthor) see **Crismon, M. Lynn,** 103
Jew, Lyle J. (author) Inhaled Aminoglycosides in Cystic Fibrosis (DIAS) 711; (author) Thalidomide in Erythema Nodosum Leprosum (DIAS) 482
Jewesson, Peter J. (coauthor) see **Bunz, Donna M.,** 546
Jimenez-Alonso, Juan (coauthor) see **Aranegui, Pedro,** 641
Jinks, Martin J. (author) A Profile of Alcohol and Prescription Drug Abuse in a High-Risk Community-Based Elderly Population (G) 971
Jirak, Jana L. (coauthor) see **Vanderveen, R. Pete,** 833
Job, Martin L. (author) Seizure Activity with Imipenem Therapy: Incidence and Risk Factors (CR) 467
Johansen, Mary J. (author) Use of Influenza Vaccine in AIDS Patients (DIAS) 837
Johnson, June Felice (author) Symptomatic Hypoglycemia Secondary to a Glipizide-Trimethoprim/Sulfamethoxazole Drug Interaction (SR) 250
Johnson, Lawrence F. (coauthor) see **Gonzalez, Edgar R.,** 1064
Johnson, Richard E. (author) Acyclovir Use and its Surveillance in a General Population (PEP) 624
Jones, James G. (coauthor) see **Ellison, Mark J.,** 682
Jungnickel, Paul W. (coauthor) see **Shaefer, Mark S.,** 472
Kaiser, Allen B. (coauthor) see **Roach, Albert C.,** 183, 788
Kamada, Alan K. (author) Possible Interaction Between Ciprofloxacin and Warfarin (SR) 27
Kando, Judith C. (author) Pergolide-Induced Hypotension (L) 543
Karam, John H. (coauthor) see **White, John R., Jr.,** 1043
Karavokiros, Kellie A. Tefakis (author) Flumazenil: A Benzodiazepine Antagonist (FF) 976
Karim, Abdul (coauthor) see **Quattrocchi, Frank P.,** 1233
Karki, Shyam D. (author) A Team Approach to Reduce Antibiotic Costs (PEC) 202; (author) Seizure with Ciprofloxacin and Theophylline Combined Therapy (SR) 595
Katz, Paul R. (author) Antibiotic Order Forms in the Nursing Home (L) 783
Kawaguchi, Yoshihiro (coauthor) see **Ueno, Kazuyuki,** 471
Keck, Paul E., Jr. (coauthor) see **Kando, Judith C.,** 543
Kelly, H. William (author) Should Anticholinergics be Used in Acute Severe Asthma? (PA) 409; (coauthor) see **Reed, Michael T.,** 868
Kelly, Janet L. (author) Hydrochlorothiazide Dosage in Hypertension (DIAS) 157
Kelly, Michael W. (author) Clomipramine: A Tricyclic Antidepressant Effective in Obsessive-Compulsive Disorder (FF) 739
Kernodle, Douglas S. (coauthor) see **Roach, Albert C.,** 183, 788
King, Mark M. (coauthor) see **Araujo, Oscar E.,** 851
Kirkland, John L. (author) Propylthiouracil-Induced Hepatic Failure and Encephalopathy in a Child (SR) 470
Kiser, Lori A. (author) Comment: Propofol Dosage (L) 102
Kluger, Jeffrey (coauthor) see **Colucci, Robert D.,** 99
Koda-Kimble, Mary Anne (coauthor) see **White, John R. Jr.,** 1043
Koeller, Jim M. (author) Rational Use of Antibiotics in the Critically Ill Patient (S) S17
Kohler, David R. (coauthor) see **Goldspiel, Barry R.,** 616
Komen, Ben J. (coauthor) see **de Flines, Egbert W.,** 783
Kortabarria, Rafael P. (author) Toxic Psychosis Following Cycloplegic Eyedrops (SR) 708
Kortebein, Michael P. (author) Comment: IV Alcohol in Prevention of Delerium Tremens (L) 1120
Kreter, Bruce (coauthor) see **Fekete, Thomas,** 438
Krick, Stacie E. (author) Severe Verapamil (Sustained-Release) Overdose (SR) 705
Krissman, Paul H. (coauthor) see **Mouser, Ben,** 286
Krol, Thomas F. (coauthor) see **Hussey, Elizabeth K.,** 678
Kuhl, David A. (author) Prophylaxis of Posttraumatic Seizures (CC) 277
Kumar, Ashir (author) Cimetidine: An Immunomodulator (A) 289
Kumpf, Vanessa J. (author) Parenteral Iron Dextran Therapy (A) 162
Labreche, Dustan G. (coauthor) see **Fish, Susan S.,** 891
Lackey, Vivian A. (author) Omega-3 Fatty Acid Supplementation in Noninsulin-Dependent Diabetes (DIAS) 258
Lackner, Thomas E. (author) Accuracy of Pharmacokinetic Dose Determination of Gentamicin in Geriatric Patients (TM) 29
Lacy, Clifton R. (coauthor) see **Raia, John J., Jr.,** 506
Lake, Kathleen D. (author) book review, 789
Lalueza, Pilar (coauthor) see **Montoro, Jose B.,** 439
Lam, Wilfred (coauthor) see **Drea, Edward J.,** 581
Lam, Y.W. Francis (author) book review, 1013
Lammers, Jan (coauthor) see **Vervloet, Erik,** 440
Lamp, Kenneth C. (author) Comment: Famotidine Stability (L) 1010
Lampkin, Thomas A. (author) Omeprazole: A Novel Antisecretory Agent for the Treatment of Acid-Peptic Disorders (FF) 393
Lamsam, Grace D. (coauthor) see **Strand, Linda M.,** 1093
Landau, Marina (coauthor) see **Brenner, Sarah,** 1007
Langnas, Alan M. (coauthor) see **Miwa, Linda J.,** 365
Laporte, Joan-Ramon (coauthor) see **de Bolos, Josep Maria Arnau,** 101; (coauthor) see **Ibanez, Luisa,** 786
Larijani, Ghassem E. (author) book review, 647; (author) Correction: Propofol Dosage (L) 102; (author) Serum Concentration of Alpha$_1$-Acid Glycoprotein and Albumin Following Cesarean Section and Vaginal Delivery (L) 328; (coauthor) see **Cummings, Doyle M.,** 229, 1010
Larsen, Robert A. (coauthor) see **Evans, R. Scott,** 351
Laucka, Paul V. (coauthor) see **Hoffman, Nannette B.,** 707
Laven, David L. (author) book review, 895
Lawler, Frank H. (coauthor) see **Ellison, Mark J.,** 682
Layne, Richard D. (coauthor) see **Abate, Marie A.,** 810
Lechner, Judith L. (coauthor) see **Morse, Gene D.,** 754
Lee, Connie R. (author) Accuracy of Home Pregnancy Tests (DIAS) 712
Lee, Mary (author) Oxybutynin-Induced Reflux Esophagitis (CR) 583
Leggett, Nancy J. (author) Cefixime (FF) 489
Leibovici, Leonard (coauthor) see **Mor, Felix,** 135, 787
Leighton, Barbara L. (coauthor) see **Larijani, Ghassem E.,** 328
Leikin, Jerrold B. (author) Nalbuphine vs. Meperidine in Sickle Cell Anemia (L) 781
Leisure, Gregory P. (coauthor) see **Bednarczyk, Edward M.,** 456
Lerner, Nurit (coauthor) see **Avisar, Rahamim,** 640
Letassy, Nancy A. (author) Nafarelin: A Gonadotropin-Releasing Hormone Agonist for the Treatment of Endometriosis (FF) 1204
Levinson, Paul (coauthor) see **Hume, Anne L.,** 1169
Lewinsky, Dana B. (coauthor) see **Mutch, Rebecca S.,** 885
Lewis, Myron (coauthor) see **Wachsman, Bruce A.,** 324
Lewis, Richard K. (coauthor) see **Hutchinson, Richard A.,** 633
Linares, Fernando (coauthor) see **Montoro, Jose B.,** 439
Lindley, Celeste M. (author) book review, 1238
Lisi, Donna M. (author) Comment: Initial Drug Noncompliance (L) 641; (author) Comment: Liver Function Tests (L) 787
London-Wong, Diane M. (author) Minoxidil with Tretinoin in Baldness (DIAS) 43
Lopez, Ana Mari (author) Clinical Pharmacy as Perceived by a Foreign Physician (L) 208; (coauthor) see **Sproat, Thomas T.,** 442
Lopez-Gomez, M. (coauthor) see **Aranegui, Pedro,** 641
Lorimer, Dorothea (author) Cardiac Dysfunction in Athletes Receiving Anabolic Steroids (DIAS) 1060
Lowy, Franklin D. (coauthor) see **Amodio, Maria I.,** 1115
Lubowski, Teresa J. (author) Methotrexate in Ectopic Pregnancy (DIAS) 387
Luck, Jerry C. (coauthor) see **Murphy, JoAnn M.,** 1001
Luzzi, Louis A. (author) Comment: Clinical Education in Rhode Island (L) 890
Lysy, Joseph (author) Drug Fever with a Shift to the Left (L) 782

M–N

Ma, Christine B. (author) Guar Gum in Hyperlipidemia (DIAS) 480
MacArthur, Robert B. (author) Comment: Cost Effectiveness of Cefazolin Compared with Cefamandole (L) 788
Macready, John J. (coauthor) see **Martins, A. Melanie,** 887
Maddox, Ray R. (author) Comment: Pharmacotherapy and Certification (L) 644; (author) Specialization and Pharmacy's Future (O) 637
Magnuson, David E. (author) Comment: Duteplase not Alteplase (L) 1236
Maliekal, James (author) Comment: Intravenous Ranitidine Admixtures (L) 1123
Malik, Mark (coauthor) see **Heiselman, Darell E.,** 1163
Maloley, Pierre A. (author) Lorazepam Dosing In Neonates: Application of Objective Sedation Scores (L) 326; (author) Severe Reversible Thrombocytopenia Resulting from Butoconazole Cream (SR) 143
Manny, Richard P. (coauthor) see **Mattingly, Paul M.,** 1172
Maponga, Charles (author) Lack of Effect of Piroxicam on Theophylline Clearance in Healthy Volunteers (RPR) 123
Marcelo, Linda (coauthor) see **Fekete, Thomas,** 438
Marcoux, Andrew W. (author) Psychotropic Drug Data Request (L) 784
Mariano, Erlinda (coauthor) see **Karki, Shyam D.,** 202
Marinac, Jacqueline S. (author) Anistreplase: A Novel Thrombolytic Agent for Acute Myocardial Infarction (FF) 607
Marken, Patricia A. (author) book review, 443
Marquis, Norman R. (coauthor) see **Shaefer, Mark S.,** 472
Martins, A. Melanie (author) Assessment of Pediatric Theophylline Measurements (L) 887
Mason, Nancy A. (author) Angiotensin-Converting Enzyme Inhibitors and Renal Function (DSP) 496
Massaro, Michael J. (coauthor) see **Voytovich, Robert M.,** 100

Mattea, Edward J. (coauthor) see **Fish, Susan S.,** 891
Matthews, Jeffrey B. (coauthor) see **Dent, John,** 1226
Mattingly, Paul M. (author) Pancytopenia Secondary to Short-Term High-Dose Intravenous Infusion of Amrinone (CR) 1172
Mauro, Laurie Slack (coauthor) see **Mauro, Vincent F.,** 252
Mauro, Vincent F. (author) Effect of Aluminum Hydroxide Gel on Quinidine Gluconate Absorption (SR) 252
McCloy, Rory F. (coauthor) see **Dent, John,** 1226
McCormick, Lisa S. (coauthor) see **Tankanow, Roberta M.,** 382
McCormick, William C. (coauthor) see **Eng, Howard J.,** 931
McDuffie, John (coauthor) see **Angell, Reginald S.,** 1009
McGhan, William F. (editor) Pharmacoeconomics, 82, 304, 422
McLeod, Donald C. (author) Author's Reply: Pharmacy Specialization (L) 1011; (author) Author's Reply: Pharmacotherapy and Certification (L) 64; (author) Boards in Clinical Pharmacology: Portent for Pharmacy and Pharmacotherapy (E) 779; (author) Pharmacotherapy: Part III. A Process of Certification (E) 95; (author) Pharmacotherapy: Part IV. The Future of Specialization and Certification in Pharmacy (E) 181
McQueen, Kellie D. (coeditor) see **Hart, Linda L.,** 40, 157, 257, 385, 475, 597, 710, 837, 951, 1059, 1179
Medicus-Bringa, Margaret A. (coauthor) see **Kortebein, Michael P.,** 1120
Meltzer, Barton A. (author) Comment: Incidence of Adverse Reactions Caused by Contrast Media (L) 547
Mergener, Michael A. (coauthor) see **Ibrahim, Osama M.,** 817
Messenheimer, John A. (coauthor) see **Hussey, Elizabeth K.,** 678
Metz, Craig A. (coauthor) see **Atra, Edgar,** 920
Meute, Margaret A. (coauthor) see **Murphy, JoAnn M.,** 1001
Meyers, David G. (coauthor) see **Dahl, Jeffrey R.,** 685
Micali, Giuseppe (coauthor) see **West, Dennis P.,** 464
Mickle, Timothy R. (author) Evaluation of Pharmacists' Practice in Patient Education when Dispensing a Metered-Dose Inhaler (RPR) 927
Middleton, Robert K. (coauthor) see **Chan, Suzanna,** 952; (coauthor) see **Jew, Lyle J.,** 482; (coauthor) see **Oliva, Christopher Carl,** 388; (coeditor) see **Hart, Linda L.,** 40, 157, 257, 385, 475, 597, 710, 837, 951, 1059, 1179
Millares, Mirta (coauthor) see **Ballard, Craig,** 41
Milavetz, Gary (editor) Pulmonary and Allergy, 409, 868
Miller, Dean M. (coauthor) see **Pane, Fred J.,** 439
Miller, Susan W. (coauthor) see **Strom, J. Grady, Jr.,** 130
Mimouni, Aviva (author) Fixed Drug Eruption Following Rifampin Treatment (SR) 947
Mimouni, Marc (coauthor) see **Mimouni, Aviva,** 947
Miraldi, Floro D. (coauthor) see **Bednarczyk, Edward M.,** 456
Miralles, Ramon (coauthor) see **Pedro-Botet, Juan,** 438
Mirtallo, Jay M. (author) Assessing the Nutritional Needs of the Critically Ill Patient (S) S20; (coauthor) see **Owens, Julie Ponting,** 585
Mitchell, Dan (author) Comment: Oral Cephalosporins (L) 642
Miwa, Linda J. (author) Drug-Induced Hypertrichosis: Case Report and Review of the Literature (CR) 365; (coauthor) see **Shaefer, Mark S.,** 472
Miyai, Kazuyoshi (coauthor) see **Ueno, Kazuyuki,** 471
Mize, Rene (coauthor) see **Maloley, Pierre A.,** 326
Mohamed, Kader N. (author) Acetarsol-Induced Stevens-Johnson Syndrome (L) 99
Montagne, Michael (author) The "Abuse" of Oxygen (L) 1118
Montgomery, Howard A. (coauthor) see **Maloley, Pierre A.,** 143
Montoro, Jose B. (author) Drop Size and Systemic Adverse Effects in Timolol Ophthalmic Solution (L) 439
Moore, John G. (author) Achieving pH Control in the Critically Ill Patient: the Role of Continuous Infusion of H_2-Receptor Antagonists (S) S28
Moore, Laura L. (coauthor) see **Fulton, Bret,** 1122
Mor, Felix (author) Authors' Reply: Liver Function Tests (L) 787; (author) Prospective Evaluation of Liver Function Tests in Patients Treated with Aminoglycosides (RPR) 135
Moriarty, Veronica (author) Comment: IV Alcohol in Prevention of Delirium Tremens (L) 1120
Morley, Peter C. (coauthor) see **Strand, Linda M.,** 1093
Morse, Gene D. (author) Zidovudine Update: 1990 (FF) 754
Mouser, Ben (author) Effect of Cimetidine on Oral Digoxin Absorption (DIR) 286
Mowers, Robert M. (coauthor) see **Ballard, Craig,** 41; (coauthor) see **Hidalgo, Hanneli A.,** 40
Mueller, Bruce A. (author) Authors' Reply: Ciprofloxacin Excretion into Breast Milk (L) 1122; (author) Impact of College of Pharmacy-Based Educational Services within the Hospital (ET) 422; (coauthor) see **Cover, Darra L.,** 703; (coauthor) see **Southwood, Robin L.,** 855
Muhlbauer, Michael S. (coauthor) see **Kuhl, David A.,** 277
Mullooly, John P. (coauthor) see **Johnson, Richard E.,** 624
Mulrow, Cynthia D. (author) book review, 1014
Munger, Mark A. (coauthor) see **Bednarczyk, Edward M.,** 456
Murphy, Christine C. (coauthor) see **Owens, Julie Ponting,** 585
Murphy, JoAnn M. (author) Amiodarone: A Postmarketing Evaluation of Monitoring for Drug-Induced Toxicity (PEP) 1001
Murphy, John E. (coauthor) see **Mouser, Ben,** 286
Murphy, Shirley (coauthor) see **Kelly, H. William,** 409
Murray, Kim M. (author) Suspected Ciprofloxacin-Induced Interstitial Nephritis (SR) 379
Mutch, Rebecca S. (author) Plicamycin: Bolus or Infusion? (L) 885
Mutnick, Alan H. (coauthor) see **Drea, Edward J.,** 548, 581; (coauthor) see **Fish, Susan S.,** 891
Myers, Carol W. (coauthor) see **Kelly, Michael W.,** 739
Nafria, Esteve Colome (coauthor) see **de Bolos, Josep Maria Arnau,** 101
Nakao, Yasushi (coauthor) see **Ieiri, Ichiro,** 629
Nappi, Jean M. (author) book review, 329
Naylor-Shepherd, Michele F. (author) Oxygen Homeostasis: Theory, Measurement, and Therapeutic Implications (CC) 1195
Neely, Jeffrey L. (coauthor) see **Abate, Marie A.,** 810
Nelson, Elizabeth (coauthor) see **Maloley, Pierre A.,** 143
Net, Alvar (coauthor) see **Rello, Jordi,** 544, 1233; (coauthor) see **Triginer, Carles,** 324
Neumann, Kurt H. (coauthor) see **Umstead, Greg S.,** 923
Nickel, Donald A. (coauthor) see **Drinka, Paul J.,** 381
Nicolau, David P. (author) Carbonated Beverages as Irrigants for Feeding Tubes (DIAS) 840; (author) Thalidomide: Treatment of Severe Recurrent Aphthous Stomatitis in Patients with AIDS (SR) 1054
Noble, Teresa A. (coauthor) see **Lackey, Vivian A.,** 258
Norris, Mark C. (coauthor) see **Larijani, Ghassem E.,** 328
North, Donald S. (coauthor) see **Marinac, Jacqueline S.,** 607
Novak, Richard M. (coauthor) see **Pryka, Randy D.,** 255
Nullet, Francis R. (coauthor) see **Ray, James B., 693**
Nunn-Thompson, Cheryl L. (coauthor) see **Brierton, Dennis,** 1232
Nwakama, Patrick E. (coauthor) see **Bailey, Robert T., Jr.,** 571
Nykamp, Diane (coauthor) see **Mouser, Ben,** 286

O–R

Ohkita, Chieko (author) Increased 6-Hydroxycortisol Excretion in Pregnant Women: Implication of Drug-Metabolizing Enzyme Induction (RPR) 814
Ohtsubo, Kenji (coauthor) see Ieiri, Ichiro, 629
O'Keefe, Eva M. (coauthor) see **Sesin, G. Paul,** 97, 206
Oles, Karen S. (author) Therapeutic Drug Monitoring Analysis Systems for the Physician Office Laboratory: A Review of the Literature (TM) 1070
Oliva, Christopher Carl (author) Anabolic Steroid-Induced Psychiatric Reactions (DIAS) 388
Olsen, Keith M. (author) Postoperative Analgesic Requirements Following Flumazenil Administration (RPR) 1159
Oren, Ran (coauthor) see **Lysy, Joseph,** 782
Oszko, Michael A. (author) Comment: Agranulocytosis from Diclofenac Illustrates Problem in Reporting ADRs (L) 1122
Ouellet, Daniele (coauthor) see **Lampkin, Thomas A.,** 393
Owens, Julie Ponting (author) Oral Anticoagulation in Patients with Short-Bowel Syndrome (CR) 585
Paap, Christopher M. (author) Comment: Aminoglycoside Volume of Distribution in Children (L) 893
Pablo, Carmelita S. (coauthor) see **Olsen, Keith M.,** 1159
Palazzolo, Dominic (coauthor) see **Drea, Edward J.,** 581
Panacek, Edward A. (coauthor) see **Bednarczyk, Edward M.,** 456
Pane, Fred J. (author) Ciprofloxacin *Staphylococcus aureus* Resistance (L) 439
Parish, Peter A. (coauthor) see **Weedle, Peter B.,** 533
Pasko, Mary T. (author) Fluconazole: A New Triazole Antifungal Agent (FF) 860
Pedro-Botet, Juan (author) Captopril Versus Enalapril: Cough Versus Pancreatitis (L) 438
Peloquin, Charles A. (author) Fighting Tuberculosis with Old Weapons (O) 883
Pelter, Mitchell (coauthor) see **Grasela, Thaddeus H., Jr.,** 1220
Perry, Paul J. (coauthor) see **Schneider, Philip J.,** 389
Pesko, Larry J. (coauthor) see **Gonzalez, Edgar R.,** 590
Pestotnik, Stanley L. (coauthor) see **Evans, R. Scott,** 351
Peters, Mark D., II (author) Nocturnal Leg Cramps (DIAS) 599
Peterson, Edward L. (coauthor) see **Pilla, Alison M.,** 575
Peterson, Steve (coauthor) see **Mitchell, Dan,** 642
Petty, Daniel E. (coauthor) see **Carter, Charles A.,** 894
Pilla, Alison M. (author) Bioimpedance Assessment of Antipyrine Pharmacokinetics Before and After Enzyme Induction (RPR) 575
Pino, Miguel A. (coauthor) see **Kortabarria, Rafael P.,** 708
Piscitelli, Stephen C. (coauthor) see **Pasko, Mary T.,** 860
Pla, Ramon (coauthor) see **Sanahuja, Jaime,** 361
Poirier, Therese (coauthor) see **Grasela, Thaddeus H., Jr.,** 1220
Pon, Doreen (author) Octreotide Use in AIDS (DIAS) 951
Ponte, Charles D. (author) A Suspected Case of Trimethoprim/Sulfonamide-Induced Localized Exfoliation (CR) 140; (author) Combined Insulin and Oral Sulfonylureas—How Sweet it *Isn't!* (L) 1234; (author) What Nonprescription Medications Are You Taking, Mrs. Jones? (L) 1118
Popovich, John, Jr. (coauthor) see **Pilla, Alison M.,** 575
Porter, William H. (coauthor) see **Toler, Steven M.,** 698
Poston, Jeff (coauthor) see **Weedle, Peter B.,** 533
Porta, Miquel S. (coeditor) see **Hartzema, Abraham G.,** 176, 310, 624, 878, 1001, 1220
Potkin, Steven G. (coauthor) see **Sramek, John J.,** 7
Powell, Dianne (coauthor) see **Windt, Paul,** 1009
Powell, George (coauthor) see **Reents, Stan B.,** 885
Presperin, Celeste (coauthor) see **Leikin, Jerrold B.,** 781
Pryka, Randy D. (author) Clinical Pharmacokinetics of Daptomycin (SR) 255
Pucino, Frank (coauthor) see **Csako, Gyorgy A.,** 26
Quattrocchi, Frank P. (author) Flecainide Acetate Administration by Enema (L) 1233
Quenzer, Ronald W. (coauthor) see **Davis, Robin L.,** 1040
Quinn, Trevor J. (coauthor) see **Blackburn, Jim L.,** 878
Raebel, Marsha A. (coeditor) see **Thompson, Dennis F.,** 262, 389, 484, 735, 841, 954, 1064, 1185
Raghavan, Murli (coauthor) see **Karki, Shyam D.,** 595
Raia, John J., Jr. (author) Angiotensin-Converting Enzyme Inhibitors: A Comparative Review (DSP) 506
Raisch, Dennis W. (author) A Model of Methods for Influencing Prescribing: Part I. A Review of Prescribing Models, Persuasion Theories, and Administrative and Educational Methods (A) 417; (author) A Model of Methods for Influencing Prescribing: Part II. A Review of Educational Methods, Theories of Human Inference, and Delineation of the Model (A) 537
Raleigh, Fred R. (author) Author's Reply: Lack of Abuse Potential with Buspirone (L) 785
Ramoran, Nelson (author) Valproic Acid in Bipolar Disorders (DIAS) 257
Ramsey, Michael K. (author) book review, 442
Ramsey, Ruthanne (coauthor) see **Strand, Linda M.,** 1093
Ransom, J. Laurence (coauthor) see **Maloley, Pierre A.,** 326
Rappaport, Harvey M. (author) Medication(?)—Not Drug (L) 890
Raschko, Raymond R. (coauthor) see **Jinks, Martin J.,** 971
Rauser, Elma H. (author) Exacerbation of Myasthenia Gravis by Norfloxacin (L) 207
Ravis, William R. (author) book review, 1126
Ray, James B. (author) Intravenous Immune Globulin for the Treatment of Presumed Quinidine-Induced Thrombocytopenia (CR) 693
Raz, Itamar (coauthor) see **Caraco, Yoseph,** 327
Reed, Michael T. (author) Sympathomimetics for Acute Severe Asthma: Should Only Beta$_2$-Selective Agonists Be Used? (PA) 868; (editor) Pediatrics, 273, 1191
Reents, Stan B. (author) Fluconazole Success After Amphotericin B and Flucytosine Failure in Cryptococcal Meningitis (L) 885; (coauthor) see **Burnett, Richard J.,** 239
Reignor, Elaine (coauthor) see **Heiselman, Darell E.,** 1163
Reilley, Thomas E. (coauthor) see **Bonfiglio, Mark F.,** 936
Rello, Jordi (author) Aseptic Meningitis Associated with Administration of OKT3 (L) 1233; (author) Effect of Continuous Arteriovenous Hemodialysis on Ganciclovir Pharmacokinetics (L) 544; (coauthor) see **Triginer, Carles,** 324
Resman-Targoff, Beth H. (author) Ketorolac: A Parenteral Nonsteroidal Antiinflammatory Drug (FF) 1098
Rey, Aixa M. (author) Administration of ACEI Test Sublingually (L) 1116
Ried, L. Douglas (coauthor) see **Forstrom, Margo J.,** 304
Rindone, Joseph P. (coauthor) see **Bourghol, Amer,** 1007
Ringer, Linda (coauthor) see **Pane, Fred J.,** 439
Roach, Albert C. (author) Authors' Reply: Cost Effectiveness of Cefazolin Compared with Cefamandole (L) 788; (author) Selecting Cost-Effective Antimicrobial Prophylaxis in Surgery: Are We Getting What We Pay For? (O) 183
Roberts, George H. (author) book review, 330, 1012
Robinson, Dennis H. (author) book review, 552
Robinson, J. Daniel (editor) Therapeutic Monitoring, 29, 1070
Rocci, Mario L., Jr. (coauthor) see **Cummings, Doyle M.,** 229, 1010
Rock, David (coauthor) see **Lysy, Joseph,** 782
Rodenberg, Howard D. (author) Clinical Utility of a Saliva Alcohol Dipstick Estimate of Serum Ethanol Concentrations in the Emergency Department (RPR) 358
Rodvold, Keith A. (coauthor) see **Pryka, Randy D.,** 255
Roglan, Antoni (coauthor) see **Rello, Jordi,** 544
Roller, Ken (coauthor) see **Lysy, Joseph,** 782
Ross, Johnanne (author) Topical Vancomycin for the Treatment of *Staphylococcus epidermidis* and Methicillin-Resistant *Staphylococcus aureus* Conjunctivitis (CR) 1050
Ross, Mary B. (coauthor) see **Tankanow, Roberta M.,** 382
Röts, Myra (coauthor) see **Vervloet, Erik,** 440
Rotschafer, John C. (coauthor) see **Garrison, Mark W.,** 267
Rozek, Susan L. (coauthor) see **Lubowski, Teresa J.,** 387; (coauthor) see **Morse, Gene D.,** 754
Rubies-Prat, Juan (coauthor) see **Pedro-Botet, Juan,** 438
Ruffalo, Richard L. (author) Aspiration Pneumonitis: Risk Factors and Management of the Critically Ill Patient (S) S12
Rune, Simon (coauthor) see **Dent, John,** 1226
Rutherford, William F. (coauthor) see **Bednarczyk, Edward M.,** 456
Rybak, Michael J. (coauthor) see **Bailey, Elaine M.,** 714; (coauthor) see **Leggett, Nancy J.,** 489

S–T

Sachtler, Gary (author) Comment: Imipenem Dosing (L) 1236
Sacristan, Jose Antonio (coauthor) see **Soto, Javier,** 1115
Safferman, Allan Z. (coauthor) see **Baldwin, Charlene M.,** 946

Sagraves, Rosalie (coauthor) see **Ponte, Charles D.,** 1118
Sahn, Steven A. (coauthor) see **Barbarash, Rick A.,** 959
Sanahuja, Jaime (author) Intramuscular Diclofenac Sodium Versus Intravenous Baralgin in the Treatment of Renal Colic (RPR) 361
Sanchez, Jose M. (coauthor) see **Triginer, Carles,** 324
Santiago, Tamara M. (author) Nitrendipine: A New Dihydropyridine Calcium Channel Antagonist for the Treatment of Hypertension (FF) 167; (coauthor) see **Doering, Paul L.,** 1078
Santora, Julie A. (coauthor) see **Morse, Gene D.,** 754
Satterlee, Grant B. (author) Comment: Desmopressin Acetate in Postoperative Bleeding (L) 1235
Savir, Hanna (coauthor) see **Avisar, Rahamim,** 640
Sayler, Debra J. (coauthor) see **DeJong, Douglas J.,** 1007
Schentag, Jerome J. (coauthor) see **Maponga, Charles,** 123
Schlanz, Karen D. (author) Penbutolol: A New Beta-Adrenergic Blocking Agent (FF) 403
Schneider, Philip J. (author) Triazolam—An "Abused Drug" by the Lay Press? (TC) 389
Schomisch, Gerald W. (coauthor) see **Drinka, Paul J.,** 381
Schwartz, Larry B. (coauthor) see **Lysy, Joseph,** 782
Schwartz, Marla T. (author) Potential Neurological Toxicity Related to Ciprofloxacin (CR) 138; (coauthor) see **Calvert, John F.,** 892
Seaton, Terry L. (author) Possible Potentiation of Warfarin by Fluconazole (SR) 1177
Seifert, Charles F. (coauthor) see **Wright, Patricia Small,** 822
Seki, Takeshi (coauthor) see **Ueno, Kazuyuki,** 471
Self, Timothy H. (coauthor) see **Mickle, Timothy R.,** 927
Sepkowitz, Douglas (coauthor) see **Gradon, Jeremy D.,** 1175
Sesin, G. Paul (author) Ceftizoxime Drug Utilization Evaluation: Empiric Versus Therapeutic Regimens (L) 97; (author) Drug Utilization Evaluation of Cefotetan Versus Cefoxitin in a Large Teaching Hospital (L) 206; (author) Drug Utilization Review of Ampicillin/Sulbactam (L) 782
Shaefer, Mark S. (author) Sensory/Mixability Preference Evaiuation of Cholestyramine Powder Formulations (SR) 472; (coauthor) see **Miwa, Linda J.,** 365
Sharifi, Roohollah (coauthor) see **Lee, Mary,** 583
Shaw, Byers W., Jr. (coauthor) see **Miwa, Linda J.,** 365
Shea, Brian F. (author) Authors' Reply: Famotidine Stability (L) 1010; (author) Stability of Famotidine in a 3-in-1 Total Nutrient Admixture (RPR) 232
Shevchuk, Yvonne M. (author) Aminoglycoside Volume of Distribution in Pediatric Patients (PED) 273; (author) Author's Reply: Aminoglycoside Volume of Distribution in Children (L) 893
Simon, Kenneth B. (coauthor) see **Taylor, Jerry W.,** 695
Sklar, Grant (author) Comment: A Process of Certification (L) 645
Skluth, Hilary A. (author) Spironolactone: A Re-Examination (A) 52
Skoutakis, Vasilios A. (coauthor) see **Carter, Charles A.,** 894
Skowron, Diane M. (author) Precaution with Titrating Nortriptyline After the Use of Fluoxetine (L) 1008
Smith, Albert J. (coauthor) see **Toler, Steven M.,** 698
Smith, Curtis L. (author) Using Estimated Creatinine Clearance for Individualizing Drug Therapy: A Reassessment (TC) 1185
Smith, Gary H. (author) Authors' Reply: Oral Cephalosporins (L) 642; (author) Oral Cephalosporins in Perspective (DSP) 45
Smith, Linda A. (coauthor) see **Barbarash, Rick A.,** 959
Smith, Richard C. (author) Desmopressin Acetate in Postoperative Bleeding (DIAS) 475
Sobotka, Jenelle L. (author) A Retrospective Study of Compliance with Recommended Hematologic Monitoring of Carbamazepine (RPR) 1166; (author) A Review of Carbamazepine's Hematologic Reactions and Monitoring Recommendations (A) 1214
Sofair, Jane B. (coauthor) see **Zito, Julie Magno,** 176
Solimando, Dominic A., Jr. (author) Comment: Pharmacy Specialization (L) 1011
Solomon, David A. (coauthor) see **Barker, David B.,** 847
Somani, Pitambar (coauthor) see **Mauro, Vincent F.,** 252
Sommi, Roger W., Jr. (author) book review, 210
Soto, Javier (author) Possible Theophylline–Amiodarone Interaction (L) 1115
Souney, Paul F. (coauthor) see **Shea, Brian F.,** 232, 1010
Southwood, Robin L. (author) Soft Tissue Calcification in Renal Failure (CR) 855
Speedie, Stuart M. (coauthor) see **Jankel, Charlotte A.,** 982
Sproat, Thomas T. (author) book review, 442
Sramek, John J. (author) book review, 330; (author) Patterns of Neuroleptic Usage in Continuously Hospitalized Chronic Schizophrenic Patients: Evidence for Development of Drug Tolerance (RPR) 7
Stanley, Ruth (author) book review, 896
Staum, John M. (author) Enzyme Induction: Rifampin–Disopyramide Interaction (CR) 701
Stein, Zephaniah L.G. (coauthor) see **Barkin, Robert L.,** 1010
Steinberg, John R. (author) Comment: Lack of Abuse Potential with Buspirone (L) 785
Stemhagen, Annette (author) Comment: Agranulocytosis Caused by Diclofenac (L) 786
Stergachis, Andy S. (coauthor) see **Forstrom, Margo J.,** 304
Stevens, Robert C. (author) book review, 553
Stewart, Ronald B. (author) book review, 1237; (author) Polypharmacy in the Elderly: A Fait Accompli? (E) 321; (editor) Geriatrics and Gerontology, 533, 971
Strand, Linda M. (author) Drug-Related Problems: Their Structure and Function (PEP) 1093
Stratta, Robert J. (coauthor) see **Miwa, Linda J.,** 365
Stringer, Kathleen A. (coauthor) see **Marinac, Jacqueline S.,** 607
Strodel, William E. (coauthor) see **Barker, Donald E.,** 235
Strom, J. Grady, Jr. (author) Stability of Drugs with Enteral Nutrient Formulas (RPR) 130
Supernaw, Robert B. (coauthor) see **Ibrahim, Osama M.,** 817
Svensson, Craig K. (author) book review, 789; (coauthor) see **Pilla, Alison M.,** 575
Tam, Carlos W. (author) Comment: Repetitive Publication of Amoxapine and NMS Case Report (L) 646
Tan, Lisa S.L. (coauthor) see **Vervloet, Erik,** 440
Tankanow, Roberta M. (author) A Double-Blind, Placebo-Controlled Study of the Efficacy of Lactinex in the Prophylaxis of Amoxicillin-Induced Diarrhea (SR) 382
Tarifi, Hashem A. (author) Drug Information Centers as Bases for Continuing Education Programs in Kuwait (IR) 769
Taylor, Deanna M. (coauthor) see **Shevchuk, Yvonne M.,** 273
Taylor, Jerry W. (author) Possible Intramuscular Midazolam-Associated Cardiorespiratory Arrest and Death (CR) 695; (coauthor) see **Cleary, John D.,** 148, 891
Temesy-Armos, Peter N. (coauthor) see **Mauro, Vincent F.,** 252
Teoh, Kok-wah (coauthor) see **Atra, Edgar,** 920
Teshima, Jeff Y. (author) Heparin in Unstable Angina (DIAS) 385
Thayer, Charles F. (author) Comment: Streptokinase-Induced Reactions (L) 546
Thomas, Robert L. (coauthor) see **Schlanz, Karen D.,** 403
Thomas, Wilkinson O.A. (coauthor) see **Ette, Ene I.,** 426
Thompson, Dennis F. (coauthor) see **Johansen, Mary J.,** 837; (coauthor) see **Letassy, Nancy A.,** 1204; (editor) Therapeutic Controversies, 262, 389, 484, 735, 841, 954, 1064, 1185
Thrasher, Kimberly A. (coauthor) see **Fish, Susan S.,** 891
Tierney, Michael G. (coauthor) see **Fong, Samantha L.C.,** 689
Tilson, Hugh H. (coauthor) see **Johnson, Richard E.,** 624; (coeditor) see **Hartzema, Abraham G.,** 176, 310, 624, 878, 1001, 1220
Timm, Edward G. (coauthor) see **Grasela, Thaddeus H., Jr.,** 1220
Titus, Danielle L. (coauthor) see **Voytovich, Robert M.,** 100
Toler, Steven M. (author) Severe Phenytoin Intoxication as a Result of Altered Protein Binding in AIDS (CR) 698
Torello, Jaume (author) Captopril-Associated Aplastic Anemia (L) 543
Townsend, Michael C. (coauthor) see **Bonfiglio, Mark F.,** 936
Townsend, Raymond J. (coeditor) see **McGhan, William F.,** 82, 304, 422
Triginer, Carles (author) Theophylline Plasma Concentrations and Silicone Central Venous Catheter: A Potential Source of Error (L) 324
Tsipis, Gaylene B. (coauthor) see **Karavokiros, Kellie A. Tefakis,** 976
Tsiu, Sandra J. (coauthor) see **Mickle, Timothy R.,** 927
Tully, Mary P. (author) Intracranial Hypertension in Association with Stanazolol Therapy (L) 1234

U–Z

Ueda, Clarence T. (coauthor) see **Dahl, Jeffrey R.,** 685
Ueno, Kazuyuki (author) Interaction Between Theophylline and Mexiletine (SR) 471
Umstead, Greg S. (author) Correlation of Free Phenytoin to Serum Albumin in Cancer Patients (RPR) 923
Underberg, Willy J.M. (coauthor) see **Beijnen, Jos H.,** 1056
Valanis, Barbara G. (coauthor) see **Johnson, Richard E.,** 624
Valley, Amy J. Wells (author) book review, 791
Vallverdu, Inmaculada (coauthor) see **Rello, Jordi,** 1233
van Arsdale, Robert W. (author) Comment: Incidence of Adverse Reactions Caused by Contrast Media (L) 547
Van Dyke, David S. (coauthor) see **van Arsdale, Robert W.,** 547
van Gijn, Roel (coauthor) see **Beijnen, Jos H.,** 1056
van Mourik, Cees H. (coauthor) see **Vervloet, Erik,** 440
van Saene, Hendrik K.F. (coauthor) see **Vollaard, Ernst J.,** 60
Van Slooten, Andrea D. (coauthor) see **Pasko, Mary T.,** 860
Vanderveen, R. Pete (author) The Pharmacist as a Health Consultant—Ten Years Later (SR) 833
Veenhoven, Willem A. (coauthor) see **de Flines, Egbert W., 783**
Veerman, Mark W. (author) Excipients in Valproic Acid Syrup May Cause Diarrhea: A Case Report (SR) 832
Vender, Tamara (coauthor) see **Avisar, Rahamim,** 640
Vervloet, Erik (author) Netilmicin Sulfate Stability in Combination with Metronidazole or Ranitidine Hydrochloride in NaCl 0.9% Infusion (L) 440
Vlasses, Peter H. (author) book review, 103, 60
Voytovich, Robert M. (author) An Aminoglycoside Dosing Regimen in a Morbidly Obese Patient (L) 100; (coauthor) see **Windt, Paul,** 1009
Wachsman, Bruce A. (author) Aminophylline via TPN (L) 324
Wagner, David K. (coauthor) see **Pryka, Randy D.,** 255
Wagner, Joel (coauthor) see **Ibrahim, Osama M.,** 817
Walawander, Cynthia A. (coauthor) see **Grasela, Thaddeus H., Jr.,** 1220
Walters, J. Ken, Jr. (coauthor) see **Grasela, Thaddeus H., Jr.,** 1220
Wandres, Daniel L. (coauthor) see **Do, Thuy Minh,** 1059
Warner, Christopher W. (coauthor) see **Davis, Robin L.,** 1040
Wasan, Suman M. (author) Considerations in Establishing Expiration Dates for Fluphenazine Decanoate Multiple-Dose Vials (L) 889; (coauthor) see **Gardner, Martha L.,** 940
Watson, William A. (coauthor) see **Rodenberg, Howard D.,** 358
Weaver, Richard L. (coauthor) see **Maloley, Pierre A.,** 326
Weber, D. Raymond (author) Nephrotoxicity from Once-Daily Dosing of Gentamicin (L) 1119
Weedle, Peter B. (author) Drug Prescribing in Residential Homes for Elderly People in the United Kingdom (G) 533
Welage, Lynda S. (coauthor) see **Grasela, Thaddeus H., Jr.,** 1220
Wells, Barbara G. (author) Verapamil in the Treatment of Schizophrenia (DIAS) 838; (coauthor) see **Cold, Julie A.,** 601
Welty, Timothy E. (author) book review, 209
West, Dennis P. (author) Altered Theophylline Metabolism in Patients with Psoriasis (CR) 464
West, Timothy E. (coauthor) see **Nicolau, David P.,** 1054
Weston, Mark W. (coauthor) see **Mattingly, Paul M.,** 1172
Whelan, Anne Marie (author) Doxepin in Smoking Cessation (DIAS) 598
White, John R., Jr. (author) Effects of Pentoxifylline on Proteinuria in Normotensive Patients with Diabetes Mellitus (RPR) 1043
Whitmore, Cherie K. (coauthor) see **Thayer, Charles F.,** 546
Wiley, Stephen W. (coauthor) see **Murphy, JoAnn M.,** 1001
Wilkerson, Marie A. (coauthor) see **Toler, Steven M.,** 698
Wilkinson, Wendy C. (coauthor) see **Murphy, JoAnn M.,** 1001
Willcox, Gordon S. (coauthor) see **Choy, Fred N.,** 592
Williams, Dennis M. (coauthor) see **Lindley, Celeste M.,** 1238
Wilson, Diane C. (coauthor) see **Choy, Fred N.,** 592
Wilson, Douglas E. (author) Validity of Information Received from Pharmaceutical Companies (L) 1117
Wilson, Malissa (coauthor) see **Murray, Kim M.,** 379
Windt, Paul (author) Equipotent Dosing of Estrogens? (L) 1009
Wirebaugh, Stewart R. (author) Apparent Failure of Edetic Acid Chelation Therapy for the Treatment of Coronary Atherosclerosis (CR) 22; (author) Reports of Erythematous Macular Skin Eruptions Associated with Diltiazem Therapy (CR) 1046
Witte, Kenneth W. (coauthor) see **Hutchinson, Richard A.,** 633
Wolf, Ronni (coauthor) see **Brenner, Sarah,** 1007
Womack, Patricia L. (author) Potassium Supplementation vs. Potassium-Sparing Diuretics (DIAS) 710
Wood, Clifton F. (coauthor) see **Gonzalez, Edgar R.,** 590
Wood, Paul A. (coauthor) see **Kando, Judith C.,** 543
Wood, R. Patrick (coauthor) see **Miwa, Linda J.,** 365
Worden, James P., Jr. (coauthor) see **Driver, Albert G.,** 826
Wright, Patricia Small (author) Toxic Carbamazepine Concentrations Following Cardiothoracic Surgery and Myocardial Infarction (CR) 822
Wulf, Bradley G. (coauthor) see **Dahl, Jeffrey R.,** 685
Wysenbeek, Arjeh J. (coauthor) see **Mor, Felix,** 135
Yamreudeewong, Weeranuj (author) Possible Hemolytic Anemia Associated with Human Insulin Therapy (L) 887
Yasur, Yuval (coauthor) see **Avisar, Rahamim,** 640
Yoshikawa, Manabu (coauthor) see **Ieiri, Ichiro,** 629
Young, Mark A. (coauthor) see **Leikin, Jerrold B.,** 781
Yukawa, Eiji (coauthor) see **Ieiri, Ichiro,** 629
Zarowitz, Barbara J. (coauthor) see **Pilla, Alison M.,** 575
Zaske, Darwin E. (coauthor) see **Garrison, Mark W.,** 267
Zatuchni, Jacob (author) Endpoints for Usage of Cardiac Drugs (L) 886; (author) Use of Digoxin in Patients with Sinus Rhythm and Heart Failure (L) 1232
Zeisler, John A. (author) Correction: Cimetidine-Induced Bradycardia (L) 1124
Zhanel, George G. (author) Cephalosporin-Induced Nephrotoxicity: Does It Exist? (TC) 262
Zijsling, Djurre H. (coauthor) see **Denig, Petra,** 87
Zito, Julie Magno (author) Self-Reported Neuroendocrine Effects of Antipsychotics in Women: A Pilot Study (PEP) 176
Zorn, Brian K. (coauthor) see **Barone, Joseph A.,** 98

ADVERTISER INDEX

American Society of Hospital Pharmacists, International Pharmaceutical Abstracts, 653, 809, 1151
Bristol Laboratories Oncology Products, Paraplatin, ifc-S, ifc-N; Centocor, a new breed of pharmaceuticals, 114, 220
Eli Lilly and Company, "Access Card" to information bank, ifc-O, ifc-D
Genentech, Inc., Activase, 33, 111, 127, 145, 217, 241, 337, 355, 435, 477, 549, 907, 1025, 1143
Glaxo Inc., Fortaz, ifc-J/A, 806, 1030, 1156, 1138; Fortaz, Zinacef, Ceftin, obc-Ja, obc-F, obc-Ma, obc-A, obc-My, obc-J
Harvey Whitney Books, A Casebook in Social and Behavioral Pharmacy, 25, 185, 309, 681; **CA/CTF,** subscription information, ibc-Ja, 122, 228, 350, 570, 673, 846, btw 850-851, btw 866-867, 949, 990, 999, 1051, 1133, 1135, 1262; **DICP,** back issues, 118, 213, 333, 505, 600, 893, bound volumes, 238, 384, 495, 580, 1178, classified advertising, 345,

448, 559, 661, 901, 1021, 1142, 1261, subscription information, 2, 120, 226, 348, 454, 568, 670, 808, 1032, 1140, 1158; **DRUGCALC,** 10, 134, 254, 371, 474, 636, 831; **Drug Therapy and Pharmacy Books, Journals, and Reprints,** 104, 214, 334, 446, 562, 666, 796, 910, 1016, 1038; **FAX reprint services,** 81, 137, 594; **Guidelines for the Administration of Commonly Used Intravenous Drugs,** 86, 144, 303; **journal of Pharmacy Technology,** subscription information, 66, 152, 323; **Medical Abbreviations,** 222, 421; **1989 Administration Guidelines for Parenteral Drug Therapy,** 201, 408, 525; **PICA,** subscription information, 93, 193, 433, 916; **Pediatric Drug Formulations,** 222, 272, 364, 488, 574, 692, 821, 975, 1077, 1194; **PharmaCE,** 108, 182, 249, 434, 542, 649, 753, 884, 989, 1127, 1158; **Pharmacoepidemiology, An Introduction, Second Edition,** 1092; **Pharmacokinetics and Pharmacodynamics, Current Problems, Potential Solutions,** 44, 161, 288, 623, 1097; **Pharmacokinetics and Pharmacodynamics, Research Design and Analysis,** 44, 156, 623; **Principles of Pharmacoeconomics,** 734, 900, 935, 1049, 1203; **Psychotropic Drug Handbook,** 5, 18, 166, 295, 425, 615, 697; **Reprints,** 768; **Rx for Pharmaceutical Science Research,** 483, 596, 867, 1058; **The Practice of Pharmacy,** 684, 813, 970

Lederle Laboratories, Pipracil IV/IM, ifc-Ja, ifc-M

Mead Johnson Oncology Products, Ifex, ifc-F, ifc-A, ifc-My, ifc-J

Miles Inc., Cipro, ibc-J/A, ibc-S, ibc-O, ibc-N, ibc-D

Personnel Placement, Arkansas, Arkansas Children's Hospital, 559; **California,** O.P.T.I.O.N. Care, Inc., 798, State Department of Health Services, 341, University of the Pacific, 448, 1148; **Canada,** Health and Welfare Canada, 1029, Universite Laval, 113, University of Alberta, 342, University of British Columbia, 663; **Delaware,** DuPont, 113; **Florida,** Florida Hospital Medical Center, 340, 450, 559, 561, 661, 665, 798, 1024, Jackson Memorial Hospital, 340, 560, 661, 800, 901, 1024, 1147, 1246, Memorial Hospital, 903, Southwest Florida Regional Medical Center, 1150, University of Florida, 343, 1142; **Georgia,** University of Georgia, 110; **Idaho,** Idaho State University, 1146, 1247; **Illinois,** Christ Hospital and Medical Center, 561, Ingalls Memorial Hospital, 903, Methodist Medical Center of Illinois, 903; **Iowa,** Drake University, 336, 801, 1261, University of Iowa, 342, 1028; **Ireland,** The Queen's University of Belfast, 341; **Japan,** International Education Services, 450, 565, 1142, 1261; **Kansas,** St. Joseph Medical Center, 1247; **Louisiana,** Xavier University, 1244; **Maryland,** National Institutes of Health, 110; **Michigan,** Detroit Receiving Hospital and University Health Center, 662, 1021, 1149, Ferris State University, 1024, MidMichigan Regional Medical Center, 561, The Upjohn Company, 662, University of Michigan College of Pharmacy, 561, VA Medical Center, 906, Wayne State University, 1148, 1246; **Minnesota,** St. Paul-Ramsey Medical Center, 344, University of Minnesota, 1028; **Missouri,** University of Missouri–Kansas City, 1247; **Montana,** St. Patrick Hospital, 1246, University of Montana, 344; **Nevada,** University Medical Center, 1146; **New Jersey,** Hoechst Celanese, 110, 219, 340, 448, 798, Morristown Memorial Hospital, 904, Our Lady of Lourdes Medical Center, 113, Radius Scientific Inc., 902, Rutgers—The State University of New Jersey, 801, Schering-Plough, 343; **New York,** Albany Medical Center Hospital, 902, Norwich Eaton, 902, Oneida City Hospital, 450, 1245, Saint Francis Hospital, 1022, St. John's University, 342, State University of New York at Buffalo, 343; **North Carolina,** Cape Fear Valley Medical Center, 663, University of North Carolina at Chapel Hill, 219; **Ohio,** The Toledo Hospital, 1021, University of Cincinnati Medical Center, 901; **Pennsylvania,** Duquesne, 1028, Hamot, 902, 1022, Harrisburg Hospital, 1247, Pharmacists for Life, 345, 1028, 1150, Philadelphia College of Pharmacy and Science, 1147, SmithKline Beecham Pharmaceuticals, 663, 906, Temple University, 341, 1244, The Allentown Hospital– Lehigh Valley Hospital Center, 904, Thomas Jefferson University Hospital, 904, 1149, University of Pittsburgh, 1142; **Texas,** Audie L. Murphy Memorial Veterans Hospital, 1261, Healthquest, 661, 798, 904, Hermann Hospital, 559, High Plains Baptist Hospital, 661, Northwest Texas Hospitals, 906, 1022, Parkland Memorial Hospital & Clinics, 1148, 1245, Texas Employment Commission, 450; **Utah,** University of Utah, 344, 905, 1023; **Virginia,** Department of Veterans Affairs, 449, 564, 664, 799, 912; **Washington,** Washington State University, 219, 1022; **West Virginia,** West Virginia University, 1146, 1245; **Wisconsin,** University of Wisconsin–Madison, 109, 216, 1147, 1244

SIMKIN, Inc., The SIMKIN Pharmacokinetics System, 266, 558, 677, 1184

SmithKline Beecham Laboratories, Eminase, 194, 314, 372, 526, 654, 772

The Haworth Press, Inc., 3 great journals for professionals and students in the pharmaceutical sciences, 639

Therapeutic Softwares, Inc., Therapeutic Software, 1244

INDEX ABBREVIATIONS

A: Article
btw: between
CC: Critical Care Therapeutics
CR: Pharmacotherapy Case Report
DIAS: Drug Information Analysis Service
DIR: Drug Interactions and Reactions Update
DSP: Drug Selection Perspectives
E: Editorial
FF: Formulary Forum
G: Geriatrics and Gerontology
ibc: inside back cover
ifc: inside front cover
IR: International Reports
L: Letters
NC: News and Comments
O: An Opinion
obc: outside back cover
PA: Pulmonary and Allergy
PEC: Pharmacoecoomics
PED: Pediatrics
PEP: Pharmacoepidemiology
RPR: Research/Practice Reports
SR: Short Reports
S: Symposium
TC: Therapeutic Controversies
TM: Therapeutic Monitoring

Statement of ownership, management, and monthly circulation (12 issues, $95 annually) of *DICP, The Annals of Pharmacotherapy*, publication no. 00126578. Owner, Harvey Whitney Books Company. Publisher, editor, and managing editor: Harvey A.K. Whitney, Jr. Headquarters of publisher, owner, and publication: 8044 Montgomery Road, P.O. Box 42696, Cincinnati, OH 45242. Known bondholders, mortgagees, and other security holders: none. Average no. of copies each issue from October 89 to September 90 and no. of copies of September 90: A. total no. copies printed (net press run) 8527, 8163; B. paid circulation (1) single copy sales 0, 0; (2) mail subscription 6193, 6057; C. total paid circulation 6193, 6057; D. free distribution 1023, 1014; E. total distribution (C+D) 7216, 7071; F. office use, left over, etc. 1311, 1092; G. total (E+F) 8527, 8163. No. of issues published annually: 12. Date of filing: 28 September 1990. Signed: Harvey A.K. Whitney, Jr., Publisher.

REPRINTS • REPRINTS • REPRINTS • REPRINTS • REPRINTS

Selected reference articles from the *journal of Pharmacy Technology* are available from Harvey Whitney Books Company.

Administration Guidelines for Parenteral Drug Therapy Part 1: Pediatric Patients; Part 2: Adult Patients
A complete two-part set of clinically oriented guidelines that go beyond the reconstitution and proper administration of drugs to focus on dosage range, adverse reactions, special precautions, and monitoring parameters.

Guidelines for the Administration of Commonly Used Intravenous Drugs
Provides guidelines for reconstitution and administration by intravenous push, intermittent infusion, and continuous infusion for more than 150 drugs; listed by generic name with trade name cross-reference.

Interpretive Clinical Chemistry Laboratory Tests
A complete overview of test procedures including an explanation of each test, its use and limitations, interfering factors, and reference values.

Drug Interferences with Amino Acid Analysis
Provides a compilation of over 50 substances and summarizes their specific interferences with amino acid analysis. Of interest to clinicians who evaluate the significance of amino acid measurements in patients.

Enclosed is ________ for the number of reprints I have indicated below.

___ ***Adult Parenteral Guidelines*** / $9.00

___ ***Pediatric Parenteral Guidelines*** / $9.00

___ Both ***Adult*** and ***Pediatric Guidelines*** / $15.00

___ ***IV Guidelines*** / $5.00

___ ***Clinical Chemistry Tests*** / $3.00

___ ***Drug Interferences with Amino Acid Analysis*** / $5.00

___ Send sample of the *journal of Pharmacy Technology.*

Name ________________________________

Address ________________________________

____

City ________________________________

State/Country ____________________ ZIP ________

Send orders to:
HARVEY WHITNEY BOOKS COMPANY
P.O. Box 42696, Cincinnati, Ohio 45242 USA
Telephone 513/793-3555 / FAX 513/793-3600

REPRINTS • REPRINTS • REPRINTS • REPRINTS • REPRINTS